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Summary 
The tetracycline (Tet) regulation system is being widely utilized for conditional transgenesis in 
cells of various species because of its tight on/off regulation, lack of pleiotropic effects, high 
inducibility and fast response times. Although the system has been successfully used in 
mammalian cells, the application in mice is not as straight forward. Published examples show 
variations in the performance of the Tet system in mice: while some applications report about 
good expression and regulation，others showed methylation of promoter sequences which was 
linked to transcriptional silencing of the cassette. However, these studies differ in the selected 
chromosomal integration sites of the Tet cassettes, the design of the cassette, the tissue 
investigated as well as the nature of the read-out. This hampers the direct comparison and the 
improvement of the system. 
The aim of this study was to characterize the performance of Tet cassettes located in a defined 
chromosomal environment in embryonic stem (ES) cells and mice and to explore strategies to 
overcome the silencing and heterogeneity of Tet induced transgene expression.  
Three chromosomal loci in the mouse genome, Rosa26, COL1A1 and Tigre loci were evaluated 
for doxycycline induced expression. Although elevated expression levels have been observed in 
COL1A1 and Tigre loci in es cells compared to the expression in the Rosa26 locus, neither of 
them was capable of supporting expression of Tet cassettes upon differentiation, indicating that 
in all these sites expression is compromised. Further characterization indicated the involvement 
of DNA methylation. It was investigated if chromosomal shielding elements such as the chicken 
chromatin insulator cHS4 can prevent silencing of the Tet cassettes and stabilize the expression. 
Indeed, the introduction of cHS4 insulators into the Tet cassette resulted in partial rescue of 
expression in ES cells that was stable even after differentiation of the cells.  
Furthermore, within this study, a novel strategy was designed to reactive the silenced Tet 
promoter in an active and targeted way. For this purpose, the catalytic domain from the ten 
eleven translocation methylcytosine dioxygenase 1 (TET1) was employed. This protein has been 
previously shown to induce the demethylation of methylated CpGs. To specifically recruit the 
catalytic active domain of the TET1 to the Tet promoter a tripartite fusion protein was designed 
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comprising the dioxygenase catalytic domain, the Tet promoter binding domain as well as the 
VP16 transactivating domain. This fusion protein was evaluated with respect to activate the Tet 
promoter. After expressing the fusion gene in ES cells, a significant increase of the transgene 
expression was observed which was dependent on the inducer doxycycline. This suggests that 
silencing of the Tet promoter can be overcome. Importantly, application of the expression vector 
in transgenic mice by hydrodynamic tail vein injection showed that the silenced Tet cassettes 
could even be reactivated in mice. In conclusion, this novel strategy to overcome silencing of the 
Tet promoter represents a promising approach to reactivate epigenetically silenced Tet promoter 
in vitro and in vivo. 
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Zusammenfassung/ kurzfassung 
 
Die Tetracycline (Tet) regulierten systeme, unter Verwendung von Doxycycline induzierten 
Promotoren, werden häufig verwendet um eine konditionale Genexpression transduzierter Gene 
in Zellen verschiedener Spezies zu generieren, da diese Systeme eine besonders strikte 
Genregulation ermöglichen (an/aus), keine pleiotropen Effekte, sowie eine hohe Induzierbarkeit 
und kurze Antwortzeiten aufweisen. 
Obwohl diese Systeme erfolgreich in Säugerzellen angewendet werden konnten, ist die 
Anwendung im Mausmodell nicht so geradlinig. Verschiedenste Publikationen zeigen 
Variationen im Verhalten des Tet-Systems im Mausmodell: einerseits wurde gezeigt, dass eine 
gute Expression und Regulation erreicht werden kann; andererseits wurde jedoch berichtet, dass 
die eingebrachten Kassetten epigenetisch „gesilenced“ werden, was auf die beobachtete 
Methylierung der Promotorsequenzen zurückgeführt werden konnte. Interessanterweise 
unterscheiden sich jedoch in all diesen studien die chromosomalen Integrationsorte, das Design 
der Kassetten, die verwendeten Gewebe als auch die Art der Auswertung. 
Das Ziel dieser Arbeit bestand darin das Verhalten der Tet-Kassetten in embryonalen Stamzellen 
(ES-zellen) sowie in Mäusen zu charakterisieren und Strategien zu entwickeln das 
„silencing“ dieser Doxycycline-induzierbaren Promotoren zu verhindern, um somit eine 
homogenere und stabilere Genexpression zu erhalten. 
Die erste Strategie verfolgte die Integration der Doxycycline-kontrollierten Kassetten in drei 
definierten chromosomalen Abschnitten (Rosa26, COL1A1 und Tigre Lokus) und die 
Untersuchung der Regulierbarkeit und Expression des Transgens. Obwohl vergleichsweise 
erhöhte Expressionslevel im COL1A1 und im Tigre Lokus in ES-Zellen gefunden wurden, 
konnte keiner der drei Integrationsorte die Expression der Tet-Kassette auch nach 
Zelldifferenzierung unterstützen. Nähere Untersuchungen zeigten, das DNA-Methylierung hier 
eine Rolle spielte.  
Aus diesem Grund befasste sich die zweite Strategie mit der Modifikation der „targeting“- 
Kassette. Hierfür wurde der Doxycyclin-induzierte Promoter von dem „chicken HS4 
insulator“ (cHS4) umrahmt. Durch die Anwesenheit des cHS4 konnte die Expression der 
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targeting- Kassetten erhöht und stabilisiert werden. Zudem ermöglichte die Integration des cHS4 
eine teilweise erhaltene Expression des Transgens auch nach Zelldifferenzierung. 
Des Weiteren wurde eine dritte Strategie entwickelt, welche die Reaktivierung bereits 
„gesilencter“ Promotoren ermöglichen sollte. Für diesen Zweck wurde die aktive katalytische 
Domäne der „ten-eleven translocation methylcytosine dioxygenase 1“ (TET1) mit dem reversen 
Tetrazyklin Transaktivator rtTA, ein Tetrazyklin kontrolliertes Transaktivator Protein, fusioniert. 
Das Protein TET1 wurde zuvor beschrieben eine Demethylierung von methylierten CpGs zu 
induzieren. Aufgrund dieses Fusionsproteins kann die TET1 katalytische Domäne direkt und 
Doxycycline-abhängig an den Tet-Promoter rekrutiert werden, da der rtTA nur in der 
Anwesenheit von Doxycycline an die Operator-Sequenzen des Tet-Promoters bindet. Somit 
sollte der Tet-Promoter induzierbar demethyliert und reaktiviert werden können. 
Nachdem das Fusionsprotein transient in „getargeten“ ES-Zellen exprimiert wurde, konnte eine 
signifikant erhöhte Expression der Reportergene beobachtet werden, welche abhängig vom 
Indikator Doxycycline war. Diese deutet darauf hin, dass ein „silencing“ des Tet-Promotors 
überwunden werden kann. Beeindruckend, auch die Anwendung dieses Expressionvektors im 
Mausmodell ermöglichte eine Reaktivierung „gesilenc’ter“ Transgenexpression. Hierzu wurde 
die Genexpressionskassette über hydrodynamische Injektion in zwei unterschiedlichen 
transgenen Tierlinien eingebracht und seine Wirkung untersucht. In beiden Fällen führte die 
transiente Integration zu einem signifikanten Anstieg des Reportergens. 
Zusammenfassend zeigt sich diese neuartige Strategie als sehr vielversprechend das 
„silencing“ des Tet-Promotors in vitro und in vivo zu überwinden und zeigt sich ebenfalls 
erfolgreich in der  Reaktivierung zuvor „gesilencter“ Tet-Promotoren. 
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1.  INTRODUCTION  
 
1.1 TRANSGENSIS	  
 
Genetically modified animal models are powerful tools in experimental and applied biology. The 
expression of heterologous genes (transgenes) in host allows the researchers e.g. to study the 
functionality of genes in vivo, to establish pathologic models for human disease and also enables 
the production of pharmaceutical proteins.  
For the generation of transgenic animals, zygote modification and ES cell mediated transgenesis 
are broadly used. Via these methods the transgenes are stably integrated into the genome of the 
host and support long-term expression. There are two patterns of the insertion of transgenes into 
the host genome: random integration and targeted integration. 
 
1.1.1	  	  	  	  Random	  transgene	  integration	  and	  problems	  
 
Since Gordon and his colleagues established the first transgenic mouse by pronuclear injection 
(PI) of a foreign DNA sequence into zygotes 30 years ago (Gordon, Scangos, Plotkin, Barbosa, 
& Ruddle, 1980), transgenesis was attracting increasing attention of scientists. Accordingly, this 
led to the fast progress in developing new technologies to transfer foreign DNA to recipients like 
DNA microinjection (Bishop & Smith, 1989) or ES cell modification (Bartlett, 2010). However, 
these methods are hampered by the uncontrollability of transgene expression. The first drawback 
that might influence transgene expression is unpredictable copy number (Ashe et al., 2008) since 
multiple-copy integration frequently led to tandem transgene arrays.These would induce so-
called repeat-induced gene silencing (RIGS) caused by heterochromatin formation (Garrick, 
Fiering, Martin, & Whitelaw, 1998). Moreover, random insertion of transgene could also pose 
the transgene susceptible to the position effect which is induced by the neighbouring elements 
like ubiquitous chromatin opening elements (UCOEs), Locus control regions (LCRs) and 
Scaffold/matrix attachment regions (S/MARs) (Allshire, Javerzat, Redhead, & Cranston, 1994; 
Argyros et al., 2011; Yao et al., 2003; F. Zhang et al., 2010a).Vice versa, the transgenes could 
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also exert impacts on endogenous gene expression. In order to avoid these drawbacks and 
achieve predictable and reliable transgene expression, strategies for targeted transgenesis in a 
defined genomic locus have been explored and utilized in generating transgenic cell lines and 
animals. 
 
1.1.2	  	  	  	  Targeted	  transgenesis	  
 
As discussed in the previous chapter, random integration results in unexpected interactions 
between transgenes and the host genome. This limits the reliability of transgene expression. 
Therefore, targeted integration was preferred by researchers later on (Papapetrou et al., 2011). 
To achieve targeted genomic editing, homologous recombination (HR) is widely used. HR is 
providing an exchange of nucleotide sequences between two similar or identical molecules of the 
DNA. For this purpose, double-strand breaks (DSBs) are always performed together with HR to 
fulfill high HR efficiency. In order to actualize site-specific DSBs, three major engineered DNA-
binding proteins have been exploited to date: zinc finger (ZF) nucleases based on eukaryotic 
transcription factors (Maeder et al., 2008), transcription activator-like effector nucleases 
(TALENs) derived from Xanthomonas bacteria (Hillen & Berens, 1994; Maeder et al., 
2008),  and most recently the RNA-guided DNA endonuclease Cas9 from the type II bacterial 
adaptive immune system CRISPR (Cheng et al., 2013; Cong et al., 2013; Fu et al., 2013; 
Gasiunas, Barrangou, Horvath, & Siksnys, 2012; Hsu, Lander, & Zhang, 2014; Sapranauskas et 
al., 2011; Xue et al., 2014). 
 
1.1.2.1	  	  	  	  RMCE	  
 
Site specific recombinase mediate cassette exchange (RMCE) is a powerful tool for targeted 
transgenesis which have been successfully utilized to achieve predictable gene expression in cell 
culture and transgenic animals (Kues et al., 2006). Two RMCE systems are widely exploited: (i) 
Cre/loxP mediated cassette exchange and (ii) FLP/FRT mediated cassette exchange. In these 
systems the Cre and FLP are recombinases which could recombine a pair of short target 
sequences called the loxP sequences or FRT sequences. In this way cassette exchanges are 
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achieved between the same FRT/loxP sites (Nehlsen, da Gama-Norton, Schucht, Hauser, & 
Wirth, 2011) . 
To establish a transgenic mouse by RMCE all the embryonic stem (ES) cells need to be tagged, 
i.e. the insertion of two different FRT sites into the target chromosal locus (eg. Rosa26) by 
homologous recombination (HR) (An et al., 2012; Sandhu et al., 2011). After that the vector that 
comprises the gene of interest (GOI) flanked with the same FRT sites in a proper orientation has 
to be transfected to the cells together with the FLP recombinase (Baer & Bode, 2001). In this 
way the GOI will integrate into the previously modified genomic locus.  
 
Figure 1.  Principle of RMCE. A plasmid comprising the FRT sites flanking the GOI (gene of interest) was co-
transfected with FLP recombinase, which results in the cassette exchange between the same FRT sites and FRT 
mutant (FMut) sites in the cells. 
 
1.1.3	  	  	  	  Characterized	  chromosomal	  loci	  in	  the	  mouse	  genome	  
 
A huge number of potential integration sites exist in the mouse genome, but only few are 
characterized for transgene expression. Importantly, the performances of the cassettes in the 
different loci are not predictable and have to be tested experimentally. A number of genomic loci 
have been used to integrate transgenes up to now and the most important loci relevant for this 
thesis are described in the following briefly. 
 
Introduction 
8 
 
1.1.3.1	  	  	  Rosa26	  locus	  
 
Rosa26 locus was first identified by Soriano and his coworkers in mouse embryonic stem (ES) 
cells in 1991. Its virtues of ubiquitous expression in all tissues and frequently observed gene 
targeting events in mouse ES cells inspired people to introduce transgenes into this locus. 
Afterwards, more than hundred mouse lines expressing various transgenes in this locus were 
established successfully using different strategies (Casola, 2010).  
Rosa26 locus is located on chromosome 6 and transcribes three mRNAs with unclear function. 
Disruption of these transcripts does not lead to any observed negative effects on animal’s life 
(Zambrowicz et al., 1997). In respect to the above mentioned advantages Rosa26 locus became 
one of the most popular loci applied for targeted transgene expression. 
 
1.1.3.2	  	  	  COL1A1	  locus	  
 
The COL1A1 locus is located on chromosome 17 and encodes type I collagen which is 
expressed in most connective tissues. COL1A1 was found to be a good candidate for targeting 
because it is highly expressed in fibroblast and ES cells. Because the transgenes were always 
integrated into the 3’ region of CoLlAI, no impair of CoL1A1 expression has been observed up 
to now. Also doxcycline-induced transgene expression cassettes have been introduced into this 
locus. Of note, regulated expression was reported both in vitro and in vivo (Krestel et al., 2004; 
Pichlmair et al., 2012; Yu et al., 2013)(Beard, Hochedlinger, Plath, Wutz, & Jaenisch, 2006a; 
Prockop & Kivirikko, 1995; Stadtfeld, Maherali, Borkent, & Hochedlinger, 2010). 
This locus is well characterized and depicted in Figure S1. The targetable ES cell line is tagged 
with one FRT site in COL1A1 and was established by Beard et al. (Beard, Hochedlinger, Plath, 
Wutz, & Jaenisch, 2006b). The targeting of this locus includes a complete integration of the 
plasmid (Figure S1b). The whole bacteria backbone was integrated to the endogenous Collagen 
locus through FRT wt sites by recombinase mediated cassette exchange (RMCE). This targeting 
strategy is different from that for the Rosa26 locus (Fig S1a). 
 
1.1.3.3	  	  	  	  Tigre	  locus	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The Tigre locus, referring tightly regulated locus, is a recently discovered targeting candidate. It 
was identified in 2008 by Zeng and his coworkers. The Tigre locus is located on chromosome 9 
encoding for the AB124611 gene and Carm 1 gene. Furthermore, no lethality has been observed 
by transgene insertion (Zeng et al., 2008). Importantly, the Tigre locus was screened specifically 
for regulated transgene expression using Tet cassette, which made it different from the 
previously mentioned loci (Zeng et al., 2008). 
 
1.1.3.4	  	  	  	  Other	  loci	  
 
Besides the characterized genomic loci highlighted above, there are also other loci: Hipp11 (H11) 
is named by Hippenmeyer et al. and is located on chromosome 11; H2-Tw3 is located on 
chromosome 17 and encodes a non-classical major histocompatibility complex (MHC) antigen 
(Olivares-Villagómez et al., 2011) and the Hprt locus is located on the X chromosome encoding 
an enzyme required for the salvage pathway of purine biosynthesis. All of these loci have been 
reported to shield transgene expression without disturbing endogenous gene expression (Palais et 
al., 2009). 
 
1.1.4	  	  	  	  Inducible	  promoters	  for	  controlled	  transgene	  expression	  
 
As the name implies, inducible promoters exhibited the capacity of controlled transcription 
activity induced by the presence or absence of inducers (biotic or abiotic factors). This property 
makes inducible promoters useful tools in genetic engineering as the transgene expression could 
be temporally and spatially controlled. Synthetic inducible promoters as well as natural inducible 
promoter exist. Currently, the Tet promoter is the most commonly and widely used synthetic 
inducible promoter, which is also used in this thesis. 
 
1.1.4.1	  	  	  Advantages	  of	  inducible	  expression	  of	  transgenes	  
 
An uncontrolled expression of a transgene might lead to disability of the transgenic animal or 
embryonic lethality mediated by overexpression of potentially toxic genes. This might hamper 
further studies and lead to the silencing of transgenes.  
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Benefiting from the regulated expression systems it is possible to switch on the transgene 
expression in the target cells at favored time point and thereby rule out the disadvantages brought 
by constant promoters (Belteki et al., 2005). Furthermore, regulated expression systems allow the 
induction of different expression phenotypes in the same mouse, thereby allowing to analyze the 
kinetics (Haenebalcke et al., 2013). 
 
1.1.4.2	  	  	  	  The	  tetracycline	  inducible	  promoter	  
 
The tetracycline (Tet) inducible promoter, which can be induced by tetracycline (or its derivate 
doxycyline), is a synthetic promoter that consists of several (usually seven) tandem repeats of the 
19 bp bacterial Tet-operator (Tet-O) sequence separated by spacer sequences combined with a 
minimal eukaryotic promoter (normally derived from the Cytomegalovirus promoter, designated 
as CMV mini).  
The Tet-inducible systems can be subclassified into the Tet-on system and the Tet-off systems, 
which differ in the used transactivators. In the Tet-On system, reverse tetracycline-controlled 
transactivator protein (rtTA) is disassociated from the Tet–O sequences in the presence of 
doxycline. And the absence of doxycycline induces inactivated transgene expression by binding 
of rtTA to the Tet-O sequences (Figure 2). In contrast to that, in the Tet-Off system, the situation 
is opposite. The transactivator protein (tTA) binds to the Tet-O in absence of doxycycline and 
activates the transgene expression, while the transgene expression is inactivated in the presence 
of doxycycline. (Loew, Heinz, Hampf, Bujard, & Gossen, 2010) 
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Figure 2: Principle of Tet-On inducible system. The classical Tet promoter is composed of a minimal CMV 
promoter which has only the TATA box for initiation of transcription, 7 Tet operation regions for rtTA recruiment 
and spacers in between of the Tet operators .In the Tet-On system, the reverse tetracycline-controlled transactivator 
protein (rtTA) is disassociated from the Tet operator sequence in the absence of doxycycline and induces inactivated 
transgene in presence of doxycycline.  
 
 
1.2	  	  	  EPIGENETIC	  MODULATION	  OF	  TRANSGENE	  EXPRESSION	  
 
1.2.1	  	  	  	  Epigenetic	  modifications	  
 
Interestingly, the entire human population irrespective of genders, races or age periods shares 
99.9% identical sequences. However, we still differ from each other in a thousand ways. 
Researchers are inextricably bogged down in the torturing of the question “what is the other 
recipe beyond DNA”. In 1942 the word “epigenetics” was first coined and defined by Conrad 
Waddington. From the word “epi” referring “above” literally, one could grip the point of this 
word with consummate ease as “something happened above genetics”, which is quite close to its 
official definition “causal interactions between genes and their products which bring the 
phenotype into being” (Livingstone, 2012; Sui, Price, Li, & Chen, 2012). 
Introduction 
12 
 
Lots of publications were followed afterwards on the subject of epigenetics, which proved that 
the influence of epigenetics on gene expression is in a controlled and selective manner and even 
inheritable. Several epigenetic mechanisms interfering gene expression have been discovered up 
to now. DNA methylation and chromatin remodeling play central roles in epigenetic 
modification (Pai, Bell, Marioni, Pritchard, & Gilad, 2011; Ptashne, 2007), as well as 
microRNAs and sRNAs mediated modifications (Mattick, Amaral, Dinger, Mercer, & Mehler, 
2009; Meyer, 2013), RNA transcripts and their encoded proteins induced transcription boost or 
abate (Howden et al., 2013) and non-DNA inheritance systems conducted by structure (Sapp, 
1991). 
 
1.2.1.1	  DNA	  methylation	  
 
In DNA methylation, CpGs play a critical role. CpG sites are the DNA regions with a significant 
higher amount of binucleotides, which consist of a cytosine nucleotide next to a guanine 
nucleotide and linked by a single phosphate in the linear sequence. These sites are prone to DNA 
methylation (Jabbari & Bernardi, 2004; Nan, Meehan, & Bird, 1993). When a methyl group is 
deprived from the substrates S-adenosyl-L-methionine (SAM) and then adds to the 5’ position of 
cytosine, a 5-methylcytosine in CpG site is formed. This process is mediated by DNA methyl-
transferases (DNMTs) (Ashe et al., 2008; Jaenisch & Bird, 2003) (Figure 3). 
 
Figure 3: Mechanism of DNA methylation at cytosines. DNA methylation reactions are catalyzed by DNA 
methyltransferase (DNMT) in the way of depriving a methyl group from S-adenosyl methionine (SAM) to the 5’ 
position of cytosine and form 5-methylcytosine.  
 
Condensed methylated regions of CpG sites are tending to be located near a transcription start 
sites, within gene promoter regions and enhancer regions (Dahl, Grønbæk, & Guldberg, 2011; 
Ndlovu, Denis, & Fuks, 2011). Condensed methylated CpG areas in the genome tend to be 
silenced or at least are less transcriptionally active, especially when they are located in the 
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promoter regions of the genes. Methylation patterns can also be inherited from parents into the 
zygote, which makes the methylation codes pass on from generation to generation (Choy et al., 
2010). The proposed mechanism of gene regulation is the competition of binding between 
transcription factors and methylation recruited co-repressors to the DNA. Once methylcytosines 
are formed, a complex composed of methyl CpG binding protein 2 (MeCP2) (Nan et al., 1993), 
Histone deacetylase (HDAC) and methyl binding proteins (MBPs) 1–4 (Meehan, Lewis, 
McKay, Kleiner, & Bird, 1989; Nan et al., 1993) are speedily summoned and occupy the 
methylated region. This impedes the binding of the transcription factors such as transcription 
initiation factor (TAF), TATA-binding protein (TBP) and RNA-polymerase 2. As long as the 
transcription factors can not access and have no chance to bind the DNA, transcription can not be 
initialized and the expression of gene will be switched off or silenced (Newell-Price, Clark, & 
King, n.d.) (Figure 4). 
 
Figure 4: Mechanism of DNA methylation induced gene suppression. Unmethylated DNA could form a loose 
loop, which allows transcription factors such as transcription initiation factor (TAF), TATA-binding protein (TBP), 
and RNA-polymerase 2 to bind to the DNA. This initiates the transcription. Once a certain level of cytosines in CpG 
sites is achieved, the chromatin can not maintain at a loose status. Instead, MeCP2, HDAC and MBPs will be fast 
recruited to the region and compact the genome to a status of inaccessibility. As a result other transcription factors 
can not get in touch with DNA and gene expression is repressed (Gupta et al., 2010). 
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1.2.1.2	  	  	  Passive	  and	  active	  DNA	  demethylation	  
 
Importantly, DNA methylation is reversible or can even be impeded. Methyl groups from 
nucleotides can be removed by a process called DNA demethylation. The process of DNA 
demethylation can be divided into two types: passive DNA demethylation and active DNA 
demethylation.  
 
Passive DNA demethylation and DNA methyl-transferase (DNMT) inhibitors 
The passive DNA demethylation is unnatural and mediated by DNMT inhibitors when 
replications are taken place and new DNA strands are synthesised. 5-azacytidine (Aza) is a 
chemical analogue of the cytosine nucleoside which induces the inhibition of DNMTs through its 
incorporation into DNA and RNA (Pedram et al., 2006; Stresemann & Lyko, 2008). When 
DNMTs recognize azacytosine-guanine dinucleotides, methylation process will be initiated by a 
nucleophilic attack which establish a covalent bond between the enzyme and the carbon-6 atom 
of the cytosine (Lübbert, 2000). Unlike what will happen to the natural cytosine, this bond 
formed between Azacytosine and the enzyme could not be resolved by beta-elimination through 
the carbon-5 atom, because carbon-5 in Azacytosine has been replaced by nitrogen. This 
mechanism enables an inhibition of DNMTs by treatment with Aza. DNMTS can not function 
appropriately and DNA methylation process is blocked. Importantly, in consideration of the fact 
that this blocking effect could only be exerted when azacytosine incorporated into the genome, 
azacytosine induced DNA methylation is restricted to proliferating cells (Stresemann & Lyko, 
2008). 
Decitabine is a hypomethylating agent. It is another chemical analogue of the 
cytosine (Kantarjian et al., 2006; Stresemann & Lyko, 2008). Decitabine hypomethylates DNA 
by inhibiting DNMTS in the same manner like Aza. In contrast to Aza, Decitabine can only 
incorporate into DNA chains and not into RNA chains  
 
Active DNA demethylation and the role of TET proteins 
The blocking of DNA methylation is an induced, non-natural process. Instead, active DNA 
demethylation mechanisms have been discovered in recent years as a natural demethylation 
process. E.g. zygote formation after fertilization which is entirely independent of neither DNA 
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replication nor any help from utilization of extra external chemicals displays a high reduction of 
methylation of 5’ cytosines (X. Li et al., 2008). This indicates the presence of an active 
demethylation mechanism in these processes. For a long time the mechanism of active 
demethylaiton in mammalian cells was not clear. However, in 2009 a breakthrough was achieved 
in mammalian cells by identifying ten-eleven translocation methylcytosine dioxygenase 1 (TET1) 
protein as an important player in active demethylation of mammalian DNA (Guo, Su, Zhong, 
Ming, & Song, 2011a, 2011b; Wu & Zhang, 2011). Afterwards TET2 and TET3 were also 
discovered as the members of the TET family. They have been also discovered exhibiting 5mC 
hydroxylase activities (Ito et al., 2010). There are several highly conserved domains found in all 
TET proteins which have been demonstrated indispensable in their demethylation activities. This 
includes (i) a CXXC domain, also known as CpG-binding protein (CGBP), (ii) a  CXXC-type 
zinc finger protein which is recruited almost exclusively to clustered CpG sites especially to the 
methylated ones, and (iii) a catalytic domain which is a Fe (II)- and 2-oxoglutarate (2OG)-
dependent dioxygenase (Figure 5).  
TET1 was initially identified in acute myeloid leukemia (AML) as a fusion partner of the histone 
H3 Lys 4 (H3K4) methyltransferase and mixed-lineage leukemia (MLL) in 2003 by Lorsbach 
and his colleagues (Lorsbach et al., 2003). In 2009, Zhang and his colleagues convincingly 
showed that human TET1 protein possesses enzymatic activity capable of hydroxylating 5-
methylcytosine (5mC) to generate 5-hydroxymethylcytosine (5hmC) by oxidation of 5mC in an 
iron and α-ketoglutarate dependent manner. Of note, this conversion of 5mC to 5hmC has been 
proposed as the initial step of active DNA demethylation in mammals (Dahl et al., 2011; 
Dawlaty et al., 2011; Tahiliani et al., 2009; Williams et al., 2011; H. Zhang et al., 2010) which 
was later confirmed by various experimental systems (Guo et al., 2011a, 2011b; Wu & Zhang, 
2011). 
As 5mC has been considered long time to be a unique DNA modification in mammals, the 
discovery of 5hmC opens up the new field for regulation of DNA methylation. Researchers 
found that the levels of 5hmC are varying between different cell types and tissues. Most is found 
in the brain especially in neurons (Globisch et al., 2010; Gu et al., 2011; Kriaucionis & Heintz, 
2009; Piccolo et al., 2013; C.-X. Song et al., 2011). 
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Figure 5: The conserved structures of TET protein family. CXXC-type zinc finger protein domain (CXXC 
domain) is responsible for the binding of TET proteins with CpG sites and the catalytic domain consists of a 
Cysteine rich domain, spacer and double strand βhelix domain which exhibits 2-oxoglutarate (2-OG)- and iron (II)-
dependent dioxygenase activity. TET1 and TET3 comprise both domains while TET2 lacks CXXC domain for 
binding. Although all the TET proteins contain catalytic domains, which are composed of DSBH, Cys-rich domain 
and a spacer, slight differences in the size of each domain could still be observed which might explain the 
differences in functionality of TET family proteins. 
 
He and his colleagues came up with a potential DNA demethylation process and showed in 2011 
that TET proteins are capable oxidizing 5hmC to 5-formylcytosine (5fC) and further to 5-
carboxylcytosine (5caC). These were detectable in genomic DNA of mouse ES cells. Importantly, 
when TET1 protein has been knocked down in mouse ES cells the levels of 5fC and 5caC 
dramatically shrinked. This might imply that 5hmc catalyzed by TET proteins is the primary step 
for the demethylation cascade (He et al., 2011; Ito et al., 2011) (Figure 6). 
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Figure 6: The step-wise cytosine demethylation mechanism. After the methyl group from S-adenosylmethionine 
(SAM) is transferred to the cytosine with the catalysis of DNMTs, Fe(II)/α-ketoglutarate (a-KG)-dependent 
dioxygenases, TET proteins will revert the methylated bases of the DNA into the catalytic site by a base-flipping 
mechanism. Afterwards, the active site Fe(II) is bound by the His-His-Asp residues in TET proteins and this 
concerts the working of a-KG and water. Oxygen is utilized by TET proteins as a substrate to catalyze oxidative 
decarboxylation of a-KG and produce enzyme-bound succinate, and a reactive high valent Fe(IV)-oxo intermediate 
which then reacts with 5mC, 5hmC and 5fC to generate 5hmC, 5fC and 5caC, with a net oxidative transfer of the 
single oxygen atom to the substrate which lead to the regeneration of the Fe(II) species. 
 
1.2.1.3	  Histone	  modifications	  
 
Besides the DNA methylation, histone modifications are considered to be important epigenetic 
modifications that play a crucial role in the gene regulation. Histone modifications always occur 
on long tailed H3 and H4 histones. A large number of different histone modifications have been 
reported. They comprise for example acetylation, methylation, SUMOylation, phosphorylation, 
citrullination and ubiquitination. They are considered play a crucial role and act in e.g. gene 
regulation, DNA repair and chromosome condensation (Gupta et al., 2010; Litt, Simpson, 
Recillas-Targa, Prioleau, & Felsenfeld, 2001; N. Song et al., 2011; Sui et al., 2012). 
 
1.2.1.4	  	  	  Choromosomal	  elements	  and	  their	  proposed	  epigenetic	  modulation	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After a transgene is integrated into the recipients’ chromosomes, partial or complete loss of 
transgene expression occurs over time upon passaging, freezing or differentiation which might 
be explained by the chromosal position effects (Ellis, 2005; D W Emery, Yannaki, Tubb, & 
Stamatoyannopoulos, 2000; David W Emery, 2011). Although some researchers claim the 
position effect could be avoided by screening of some endogenous loci or single copy insertion, 
silencing problem has not been thoroughly settled by either of these solutions (Persons, Hargrove, 
Allay, Hanawa, & Nienhuis, 2003). 
However, as a mechanism for transgene silencing also spreading of the heterochromatin has been 
discussed. The spreading is frequently found in the genomes of advanced eukaryotes that 
silenced the transgene expression. Accordingly, spreading of heterochromatin might result in 
condensed chromatin and abolish the accessibility of transcription factors (Raab & Kamakaka, 
2010; West, Gaszner, & Felsenfeld, 2002). 
 
Chromatin insulators 
Chromatin Insulators, first identified in Drosophila, are DNA sequences which act as 
genetic boundary to protect target gene from the impact of enhancers or silencers in neighboring 
domains, or prevent the spreading of the upstream heterochromatin by insertion in between 
neighboring domains and target genes (Burgess-Beusse et al., 2002; Recillas-Targa et al., 2002). 
Chromatin insulators have been found naturally in the genome of eukaryotes that could form 
functional boundaries between adjacent chromatin domains, which play critical roles in gene 
regulation and genomic architecture. Two classes of chromatin insulators have been discovered 
until now: the enhancer-blocking insulators and barrier insulators (Burgess-Beusse et al., 2002; 
West, Huang, Gaszner, Litt, & Felsenfeld, 2004; C. Zhang, Huys, Thibault, & Wilson, 2012). 
The enhancer-blocking insulators are capable of interfering with enhancer–promoter interactions 
when placed between them. These act by recruiting nuclear protein CCCTC-binding factors 
(CTCF). Insulators themselves could form physical loop structures that are established through 
CTCF-mediated interactions, although this hypothesis could not account for all cases of enhancer 
blocking activity (Cuddapah et al., 2009; Guelen et al., 2008; Herold, Bartkuhn, & Renkawitz, 
2012; Hou, Dale, & Dean, 2010; Tao Li et al., 2008; Tie Li, Lu, & Lu, 2004; Ling et al., 2006; 
Ohlsson, Bartkuhn, & Renkawitz, 2010; Rubio et al., 2008; Sanyal, Lajoie, Jain, & Dekker, 2012) 
(Figure 7). 
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The barrier insulators are protecting target genes against position-effect variegation (PEV)-
a variegation caused by the silencing of a gene through its juxtaposition with heterochromatin 
(Carabana, Watanabe, Hao, & Krangel, 2011; Singer, Liu, & Cox, 2012). 
 
 
 
Figure 7. Schemes elucidate the mechanism of an enhancer blocking insulator and a barrier insulator. As 
shown in the upper part of the figure, the enhancer-blocking insulator is the DNA sequence which could efficiently 
blocks external enhancer’s activity from promoter (P1) on the target promoter (P2) when placed between them. And 
for barrier activity, the insulator should be capable of recruiting a barrier complex to prevent the spreading of 
heterochromatic domains. 
 
cHS4 insulator 
The Chicken β-globin locus is located on chicken chromosome 1 downstream of the folate 
receptor (FOLR1) gene. It is a 1.2 kb DNase I-hypersensitive site (5’HS4) region located in 
between a ~16 kb long condensed chromatin domain that sits downstream of the folate receptor 
(FR) gene and a globin cluster and functions as an chromatin insulator (Chung, J H). Barrier 
function of 5’HS4 was naturally conceived (Burgess-Beusse et al., 2002). Furthermore, upstream 
stimulatory factor1/2 (USF1/USF2) has been characterized within the 1.2kb DNase I-
hypersensitive site (5’HS4) region. USF1 and USF2 are responsible for recruiting enzyme 
complexes capable of modifying histones on adjacent region with ‘activating’ markers (Litt et al., 
2001). Moreover, vascular endothelial zinc finger 1 which functions for protecting DNA against 
DNA methylation has been identified in 5’HS4 as well (Lachner, O’Carroll, Rea, Mechtler, & 
Jenuwein, 2001). Subsequent, a CCCTC-binding factor (CTCF) recruiting domain has also been 
identified in the 1.2 kb 5’HS4 sequence. CTCF was identified years ago to support the 
Introduction 
20 
 
stabilization of long-range interactions in the nucleus and to exhibit enhancer blocking activity. 
(Bartkuhn et al., 2009; Holohan et al., 2007; Kanduri et al., 2000; Ohlsson et al., 2010) (Figure 
8). Plenty of publications followed up and showed that transgene expression could be protected 
from silencing by the insertion of single or two copies of 5’HS4 full length elements or simply 
by insertion of the core elements only (Bell, West, & Felsenfeld, 1999; Burgess-Beusse et al., 
2002; Recillas-Targa et al., 2002). 
 
 
 
Figure 8: The chicken HS4 insulator. CHS4 insulator is the 1.2 kb cis-element fragment compromising a 
hypersensitive site 4 at the 5′ end of the chicken β-globin gene. This element exhibits both enhancer-blocking 
activity and barrier activity effects cross-species. It locates between the folate receptor 1 gene and the β-globin locus 
and protects the active β-globin gene domain against heterochromatin. On the one hand, a CTCF binding site located 
in the 5′ of CHS4 insulator will recruit CCCTC-binding factor (CTCF) to exert enhancer blocking activity. On the 
other hand, VEZF1, VEZ1 and USF1/2 binding sites are used for attracting proteins for barrier activity as vascular 
endothelial zinc finger 1 (VEZF1) which is essential for resisting DNA methylation, and upstream stimulatory 
factors (USFs) which are critical for histone modification.  
 
1.2.2	  	  	  	  Crosstalk	  between	  transgene	  and	  endogenous	  genes	  
 
The crosstalk of externally introduced and integrated transgenes into recipient’s genome with the 
genomic environment has becoming a hot topic in recent years. Such a crosstalk could be 
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observed regardless of the copy number of integration and random or locus specific insertion 
(Berry, Hannenhalli, Leipzig, & Bushman, 2006; Meyer, 2013; Singer et al., 2012). For instance, 
the genomic context and chromatin structures flanking the integration sites could exert impacts 
on the integrated transgenes. It has been reported that silencing or heterogeneous expression of 
the transgene in cell clones was closely related to the endogenous genomic sequences (Cai & 
Shen, 2001; Ellis, 2005). 
Vice versa, the transgenes could also influence the endogenous genes expression. This might 
affect genes within the flanking region of integration or even distant genes which directly or 
indirectly interact with transgene by the folding of the genome (David W Emery, 2011; Kang, 
Kwon, Lee, & Seo, 2013). 
 
Impact of chromosomal integration sites on Doxycline induced cassettes  
The doxycline inducible promoter (Tet-promoter) has been broadly utilized for establishing 
transgenic animal models and cell lines for its merit of controllability. During the last decades 
people achieved impressive success as numerous transgenic cell lines and animal models with 
tight regulated expression - controlled by Doxycline treatment - have been established. By 
expressing the transactivator under control of a tissue specific promoter, even spatial (tissue-
specific) and temporal control of expression could be achieved (Beard et al., 2006b; Sandhu et al., 
2011; Thesis Kruse, 2013). However, while regulated expression was reported on ES cell level, 
expression on the level of transgenic animals seems to be heterogenous and less predictable 
(Bao-Cutrona & Moral, 2009; Thesis Kruse, 2013). Previous results suggest that unexpected 
expression patterns of tetracycline-regulated transgenes in animals and cells (Bao-Cutrona & 
Moral, 2009) were observed with increasing frequency. In some studies employing the Tet 
system to the central nervous system (CNS), the reactivation of transgene was hardly achieved at 
high level (Krestel et al., 2004; S. Uchida et al., 2006). They explained the observation by a 
weak PTet/PTetbi activation in adult mice or PTet/PTetbi susceptibility to silencing which might 
be induced by DNA methylation (Kues et al., 2006). These observations lead the scientist 
increasingly to the questions why the transgene expression was not foreseeable and how the 
mechanisms could be controlled.  
Several ES cell lines and mouse strains have been established in our lab applying Tet induced 
transgene expression. Surprisingly, heterogeneous expression patterns have been observed in all 
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ES cell lines and mouse strains which contained a single copy insertion of Tet cassette in Rosa26 
locus, irrespective of the version of Tet promoter or the types of transgene. Methylation analysis 
on Tet promoter region from the existing ROSA GFP mice (Thesis Spencer, 2014) revealed 90-
99% methylated CPGs in Tet promoter region isolated from mice or cell lines displaying low or 
no transgene expression. Interestingly, in those cells and mice the methylation level of Tet 
promoter decreased to 40-50% after Aza treatment. This indicates that DNA methylation might 
contribute to heterogeneous and low expression pattern of the Tet cassettes in the Rosa26 locus.  
 
1.2 Aim	  	  
	  
Although Tet cassettes are reliable inducible tools for many applications, the failures of Tet 
induced transgene expression have been observed in many integration sites. Since an inducible 
transgene expression is of interest for many researchers, it would be beneficial to overcome this 
challenge and establish a predictable and stable inducible transgene expression. 
Therefore, overcoming the silencing of Tet cassettes in vitro and in vivo was the aim of this 
study.For this purpose, different approaches will be investigated to rescue the expression of the 
Tet cassette. 
First of all, Tet cassette will be evaluated at different defined chromosomal integration sites 
(Rosa26 locus, COL1A1 locus and Tigre locus). Secondly, chromosomal modifiers like cHS4 
insulator will be introduced to shield the Tet cassette and the expression profile of the modified 
Tet cassette will be investigated in vitro and vivo. Last but not least, active demethylation of Tet 
cassette will also be investigated in cells and in mice in different loci by TET1.                                                                                          
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2    MATERIALS AND METHODS  
 
2.1	  	  	  	  MATERIALS	  	  
2.1.1	  	  	  	  Equipments	  
 
Table 1. Equipments 
Equipments  Manufacturers  
Autoclave  BelimedDampf Sterilisator 6-6-6 HS1, FD 
BLI system Labotect 
Gel Electrophoresis Chambers  Gibco BRL Horizontal Gel Electrophoresis 
Apparatus  
Cell Counter Guava EasyCount, Millipore 
Cell culture incubators Forma Scientific Water jacketed Incubator  
Labotect C200 
Centrifuges Beckman GS-15R  
Inflexible rotors: GSA, GS3, SS34 
Swinging rotor: HB4 
Sorvall Superspeed RC5C 
Heraeus Biofuge fresco 
Sigma 3K20 
Heraeus Megafuge 1.0 
Confocal microscopy Beckman GS-15R  
Heraeus Megafuge 1.0 
Cooling Centrifuges Sigma 3K20  
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Dionized Water Supply Heraeus Biofuge fresco 
Fast prep MP  MP Biomedcals 
Flow Cytometer Sorvall Superspeed RC5C 
Homogenizer   Inflexible rotors: GSA, GS3, SS34 
In vivo luciferase imaging Xenogen IVIS system, Caliper 
Microwave  Whirlpool 
Microscopes Zeiss, Jena, Germany 
Leica Labovert FS, Nikon TMS 
Micropipettes  Gilson  
PCR-Thermocycler Veriti 384 well Applied Biosystems, Foster City, USA  
PCR-Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
PCR Machine  T3 Thermocycler, Biometra  
pH meter  Beckman  
Pipetboy  Pipetboy IBS Integra Biosciences  
Power supplies   
 
Gibco BRL ST 504  
Biorad Power PAC 200  
Biotec-Fischer Phero-STAB 550 
Shaker  Heidolph  
Sterile Work Benches  Steril Gard Class II Type A/B3, Baker Company 
Hersafe, Heraus  
Thermomixer  Eppendorf  
Thermocycler   T3 Thermocycler, Biometra 
U.V Chamber  Hanau  
Vortex  Scientific Industries Vortex Genie 2  
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Weighing  Sartorius  
4 °C refrigerator  Liebherr  
-20° C freezer  Liebherr  
- 80°C freezer  Thermo Forma  
	  
2.1.2	  	  	  	  Plasmids	  and	  Oligonucleotides	  
 
Table 2. Plasmids 
Plasmids Nr. Features 
Luc3rTA2E 2375 This is an autoregulated tetracycline inducible 
expression cassette. 
pCAGGSflpE 2703 This vector expresses Flp recombinase driven by 
CAG promoter. The CAGGS promoter drives 
expression of FlpE. 
pCMV rtTAHTV3 3362 This vector encodes rtTA2 fused with HTV3. 
pCMVRTA2HYG 2288 This vector expresses rtTA2 under CMV promoter 
and also a hygromycine resistance. The vector was 
produce by T.May, 2002, HZI. 
PCR-Blunt K2700-20 Invitrogen 
pCRE PAC 1930 This vector expresses Cre expression plasmid  
where Cre transcription is driven by the MC1 
promoter a synthetic HSV-tk promoter and 
enhancer (Taniguchi et al., 1998) 
pFB-ZB  This vector encodes full length of TET1 and was 
kindly donated by Prof. Zhang Yi. 
pTRETight 3891 Clontech 
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TetLuc 3980 This vector encodes Tet promoter driving 
luciferase.  
 
 
Table 3. Oligonucleotides 
Oligonucleotides Nr. Sequence Purpose 
Actfwd P3188 
 
tggaatcctgtggcatccatgaaac PT-PCR 
Actrev  
 
P3189 
 
taaaacgcagctcagtaacagtccg PT-PCR 
Bi-GFPFW P5103 cgagtaggcgtgtacggtg PT-PCR 
Bi-GFPRE P5104 gctcctcgcccttgctcac PT-PCR 
Bi-LUCFW P5105 gtttttggcgtcttccatgg PT-PCR 
Bi-LUCRE	   P5106 cgtcagatcgcctggagacgc PT-PCR 
cLuc fw P5108 gtttttggcgtcttccatgg PT-PCR 
cLuc re P5109 cgtcagatcgcctggagacgc PT-PCR 
creI  
 
P3018 
 
gcctgcattaccggtcgatgcaacga Genotyping 
creII  
 
P3019 
 
gtggcagatggcgcggcaacaccatt Genotyping 
EMCV2 
 
P3432 
 
gccacgttgtgagttggata Genotyping 
EMCVNeo1 P5110 aagagtcaaatggctctcctcaagcgtatt Genotyping 
EMCVNeo2 P5111 gtctgttgtgcccagtcatagccgaatag Genotyping 
FUSIOFW P5112 ctgagacaagcaattgagctg Cloning 
FUSIORE P5113 tgagagctcttcccttcctt           Cloning 
GFP1 P5114 agctgcccgtgccctggccc    PT-PCR 
GFP2 P5114 tgtactccagcttgtgcccc     PT-PCR 
INSU1FW P5116 gctgagttggctgctgccac Cloning 
INSU1RE P5117 ccgtatcccccaggtgtctg Cloning 
INSU1seFW P5118 gtgggaggcctatataagcagagc Cloning 
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INSU1seRE P5119 gggagggacgtaattacatccctg Cloning 
INSU2chFW P5120 ggcactctgtcgataccccac Cloning 
INSU2chRE P5121 gaggaaagcgatcccgtgcc Cloning 
INSU2seRE P5122 gagtaaactcgggctatggcagg Cloning 
LucRTfwd  
 
P5071 
 
gctgggcgttaatcagagag PT-PCR 
LucRTrev  
 
P5070 
 
gtgttcgtcttcgtcccagt PT-PCR 
neorev2  
 
P1523 
 
gtcatagccgaatagcctctcc Genotyping 
PGK2fwd  
 
P4219 
 
ctagtctcgtgcagatggac Genotyping 
Rttaful 1 P5123 tacccggggagcatgtc Cloning 
Rttaful2 P5124 atgtctagactggacaagagca     Cloning 
TETALLfw P5125 aaaatctcgagggatctggatctggatctgaag
gaacaggaagctgca 
Cloning 
TETALLre P5126 aaaatgcggccgcctatggtgtgataaattggc Cloning 
TETsepse RE P5127 tggaactaatcatatgtggcct sequencing 
 
2.1.3	   	  Enzymes,	  chemicals	  medium	  and	  Kits	  
 
Table4. Enzymes, chemicals medium and Kits  
Enzymes, chemicals medium and Kits Supplier  Catalogue nr.  
50mM ß-Mercaptoethanol (500x) GIBCO  31350 
5X RLB buffer Promomega E1500 
Albumin antibody  Abcam ab106582 
Alkaline Phosphatase, Calf Intestinal (CIP) NEB M0290L 
Ascorbic acid Sigma Aldrich A4403 
Azacytidine  Sigma Aldrich  A2385-100MG  
Decitabine  Sigma Aldrich  A3656-10MG  
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DNA Loading Buffer Blue(5x) Bioline BIO-37045 
DNA/RNA AllPrep Kit  Qiagen 80204 
Doxycycline  AppliChem GmbH  A29951,0025  
Dulbecco's Modified Eagle Medium (D-MEM) 
(1X), liquid (High Glucose)  
GIBCO  61965 
FCS  Sigma F7524 
Gelatin solution 2%    Sigma G1393 
Genomic DNA isolation  Qiagen  51306  
Glumax Gibco 35050-038 
HMM Maintenance Medium Lonza CC-3197 
Inhibitor of glycogen synthase kinase 3 ß Stemgent 04-00004 
Insulin Sigma 10516 
IsoFlo®  Allbrecht GmbH  701-005-301  
Klenow Fragment (3'→5' exo-) NEB M0212M 
Knockout™ DMEM Gibco 10829-018 
KnockOut™ Serum Replacement Gibco 10828-028 
Lipofectamine 2000  Lifetechnologies  11668019  
Luciferin Synchem OHG S039 
MEM Non-Essential Amino Acids (100X), liquid GIBCO  11140 
Mitogen-activated protein kinase inhibitor(MAPKI) Stemgent 04-00006 
Monothioglycerol (MTG) Sigma M6145 
Paraformaldehyde Sigma P6148-5KG 
PCR Master Mix  p.j.k.  302004  
Pen/Strep Gibco 15140-122 
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Phusion® High-Fidelity DNA Polymerase NEB M0530S 
Saponin  Sigma 47036 
Sodium butyrate  Sigma Aldrich  B5887-250MG  
Sodium Pyruvate MEM 100 mM,(100x) liquid GIBCO  11360 
SYBR® Green PCR Master Mix  Life Technologies  4309155  
T4 DNA Ligase NEB M0202M 
Valproic acid  Sigma Aldrich  P4543-25G  
Vimentin Antibody Sigma V6630 
 
2.1.4	   	  Cell	  lines,	  mouse	  lines	  and	  bacterial	  strains	  	  
 
Murine cell lines 
Murine G4B12 ES cells: G4B12 mES cells, Hybrid ES cell line from Bl/6 and 129/ola, 
targetable in the Rosa 26 locus (Haenebalcke et al., 2013). 
NIH3T3: embryonic mouse fibroblast (MEF) cell line, ATCC CRL 1658. 
MEF:  primary murine embryonic fibroblasts isolated from the different mouse strains to serve as 
a feeder layer for murine ES cell culture. 
Human cell line 
HEK293T: human embryonic kidney cell line transformed by adenovirus type 5;, expressing 
SV40 large T antigen constitutively. 
Bacteria strain 
TOP10 E. coli: TOP10 F- mrcA ∆ (mrr-hsdRMS-mcrBC) Φ80dlacZM15, ∆lacX74 recA1  
araD139 ∆ (ara-leu) 7697 galU galK rpsL (StrR) endA1 nupG  
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2.2	  	  	  	  METHODS	  	  
2.2.1	  	  	  In	  vitro	  methods	  
	  2.2.1.1	  	  	  Agarose	  gel	  electrophoresis	  	  
 
1g of agarose were poured into microwavable flask along with 100mL of 1x TAE (40 mM 
Tris/acetate pH 7.5,20 mM Sodium Acetate, 1 mM Ethylenediaminetetraacetic acid). Then, the 
mixture was microwaved for 1-3min until the agarose was completely dissolved. Afterwards, the 
agarose solution was put stilly to cool down for 5min. Ethidium bromide (10 mg/ml) was then 
added to an appropriate volume agarose to a final concentration of approximately 0.2-0.5 µg/mL 
and poured into a gel tray with the well comb. The gel was placed into an electrophoresis 
chamber filled with 1x TAE when it got solidified. DNA samples were mixed with 5x loading 
buffer (Bioline) and loaded onto the gel. Meanwhile a molecular weight ladder (Hyperladder I, 
Bioline) was loaded to determine the size of DNA samples. The gel was running at 110V until 
the dye line was approximately 80% of the way down the gel. Gels were analyzed at last under 
UV-light (360nm).  
2.2.1.2	  	  	  	  Restriction	  analysis	  	  
 
Procedures for digesting DNA were followed by the manufacturer (NEB) and varied depend on 
the enzymes.  
Total Reaction Volume 50 µl 
DNA 1 µg 
10x NEBuffer 5 µl (1x) 
Restriction enzyme 1 µl 
Incubation time 1 hour 
H2O to 50 µl 
Incubation temperature Enzyme dependent 
 
2.2.1.3	  	  	  	  Cloning	  
 
Materials and methods 
31 
 
TET1c-rtTA cloning 
Backbone pCMV rtTAHTV3 (expressing transactivator rtTA, Nr. 3362) was digested with XhoI 
and NotI and 3536bp fragment was purified. Amplified TET1c from pFB-ZB encoding full 
length of TET1 (from prof. Zhang (Ito et al., 2010)) by introducing Xho1 and Not1 cutting sites. 
PCR products were purified and digested with XhoI and NotI and labled as TET1c. 3536bp 
fragment from the first step was then ligated with TET1c to the final vector TET1c-rtTA. To 
achieve a high fidelity of amplification, Phusion® High-Fidelity DNA Polymerase (NEB) was 
used for the PCR. The modified reaction and PCR protocol was followed. Primers for 
introducing XhoI and NotI cutting sites to TET1c fragment were TETALLfw and TETALLre.  
Reaction protocol 
Component 50 µl Reaction 
Nuclease-free water 30 µl 
5X Phusion HF  10 µl 
10 mM dNTPs 1 µl 
10 µM TETALLfw 2.5 µl 
10 µM TETALLre 2.5 µl 
Template DNA 2 µl 
DMSO  1.5 µl 
Phusion DNA Polymerase 0.5 µl 
 
PCR protocol 
STEP  TEMP  TIME  
Initial Denaturation 98°C 30 seconds 
35 Cycles 98°C 
58°C 
72°C 
5-10                                     seconds 
10-30                                   seconds 
60                                        seconds  
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Final Extension 72°C 10                                        minutes 
Hold 4°C  --- 
 
TET1c-U cloning 
Backbone TET1c-rtTA was digested with NheI and SmaI. 5500 bp fragment was purified by gel 
and treated with Klenow enzyme (NEB) to blunt the hanging tail (rtTA binding site has been 
cutted away in this way). The blunted backbone was re-ligated again T4 DNA Ligase (NEB) and 
named as TET1c-unspecific. 
R26-Tet-in-HCVsWT cloning  
Two copies of the 1200bp chicken HS4 chromosomal insulator was cloned before and behind the 
Tet promoter, respectively in the PCR-Blunt vector by blunt ligation, named as PCR-BLUNT-
INSULATOR. PTAREF1aTRE Tight 5TRSV vector which contains Tet promoter and HCV 
replicon was digested with Asis1 and MIu1and 15900bp fragment was kept as F1 for the next 
step. PCR-BLUNT-INSULATOR vector was also digested with AsisI and MluI and 2500bp 
fragment (insulator) was isolated and ligate with F1. R26-Tet-in-HCVsWT has been cloned. 
Then PCR-BLUNT-INSULATOR vector was cut by SwaI and AloI and the 5200 bp fragment 
was kept. The R26-Tet-in-HCVsWT was also cut by SwaI and AloI and the 18000bp fragment 
was kept. 5200 bp fragment and 18000bp fragment were ligated to the final TetinHCVasrWT 
vector. Sequences of the insertion fragment were characterized by DNA sequencing performed 
by the sequencing facility in HZI. 
 
2.2.1.4	  	  	  Dephosphorylation	  of	  5´-­‐ends	  of	  DNA	  using	  CIP	  in	  restriction	  enzyme	  reaction	  	  
 
Total reaction volume 20 µl 
DNA 10 µg 
10X NEBuffer 2 µl (1X) 
CIP   1 µl 
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H2O 3 µl 
Incubation time 1 hour 
Incubation temperature 37° 
 
2.2.1.5	  	  	  	  A-­‐Tailing	  with	  klenow	  fragment	  (3'-­‐-­‐>5'	  exo-­‐)	  
 
Total reaction volume 50 µl 
Purified blunt DNA 30 µg 
10X NEBuffer 2 5 µl  
Klenow fragment (3´→ 5´ exo–) 3 µl 
dATP (10 mM) 1 µl 
H2O 11 µl 
Incubation time 30 min 
Incubation temperature 37° 
 
2.2.1.6	  	  	  	  	  Ligation	  of	  DNA	  fragments	  
 
COMPONENT 20 µl REACTION 
10X T4 DNA Ligase Buffer 2 µl 
Vector DNA  50 ng (0.020 pmol) 
Insert DNA  500 ng (0.060 pmol) 
Nuclease-free water to 20 µl 
T4 DNA Ligase 1 µl 
 
2.2.1.7	  	  	  	  RT-­‐PCR	  from	  tissues	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Tissues preparation 
RNAse free Eppendorf tubes and RNAse free tips and pipettes were used during the whole 
procedure. 
Freezing organs 
Mice were sacrificed by CO2 and the organs were taken out and lanced into small pieces 
(25mg/tube), then transferred to prepared labeled freezing tubes as fast as possible due to RNA 
degradation. Afterwards, the tubes were immediately immersed into the liquid nitrogen and 
could be stored up to 1 year in -80°C. 
RNA isolation 
The frozen samples were taken out and placed on ice. The samples were transferred into 
homogenizing tubes filled with 2 homogenizing beads and 600µl RLT buffer (RNeasy Lysis 
Buffer, Qiagen) including ß-mercaptoethanol (10 µl β- mercaptoethanol/ ml RLT). Samples were 
then homogenized with the fast prep MP (MP Biomedcals, Cat.no.116004500) using the 
following settings: Time: 10sec, Rpm: 450. Homogenization was repeated for 3 times and in 
between steps samples were kept for 5 min on ice. The following procedures were followed 
according to the manufacturer’s instructions (RNeasy Mini Kit, Qiagen). Briefly, after 1 min 
10000 rpm centrifugation under the fume cabinet, the samples were transfer to labeled 1,5 ml 
Eppendorf. 600 µl 70% ice-cold ethanol was added to the homogenizing products and the whole 
volume were then transfer to RNeasy spin column, which was placed in a 2 ml tube. Then the 
samples were centrifuged 1 min at 10000 rpm and flow through was discarded. 700 µl 
RW1(Wash Buffer, Qiagen) was then added to the samples and centrifuged 1 min at 10000 rpm. 
2 times washing by 350 µl and 500 µl RPE respectively was preceded before the columns were 
placed in new tubes and centrifuge 1 min full speed again. At the end, RNA was dissolved in 
35 µl RNAse free water. Concentration was determined by NANO drop. 
cDNA synthesis 
In 33µl reaction, 5 µg RNA was used for the synthesis. First diluted RNA was inoculated at 65° 
for 10 min followed by 2 min on ice. Then the reaction was initiated with the following protocol:  
COMPONENT 33 µl REACTION 
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Beads tube - 
RNA  5 ng (in 25 µl) 
Rnase free H2O 25 µl 
Oligo dT 3 µl 
The mixture was incubated for and stored at -20°C. 
RT-PCR 
The primers for amplication Actin gene	  were	  put on the same plate as a control. The primer was 
used at the concentration of 10pmol. Pipetting scheme was prepared beforehand. Water controls 
were always included as the negative control. 
COMPONENT 20 µl REACTION 
Sybr green           10 µl 
Primer forward 1 µl (10 pmol) 
Primer forward 1 µl (10 pmol) 
cDNA (1:5 dilution )   8 µl 
 
2.2.1.8	  	  	  	  	  Mammalian	  cell	  culture	  	  
 
Site-specific targeting by RMCE in cells 
5x105 G4B12 mES cells were seeded on feeders on a gelatinized 6 well plate. Transfection was 
performed in the afternoon of the next day with Lipofectamine 2000 according to the 
manufacturer’s instruction, briefly as following: 2,5 µg of pCflpe (# 2703, alternatively flpepuro: 
# 1825) and 2,5 µg of targeting vector were mixed with 250 µl pure DMEM. Then 10 µl 
Lipofectamine 2000 (Life Technologies) was added to 250 µl DMEM and inoculated for 5 min 
R.T. Both samples were then and incubated for 20 min at room R.T. 
At last 500 µl mixtures were added to each 6 well. The transfected cells were inoculated with the 
mixture overnight. One day after transfection, the cells were transferred to a 10 cm2 dish coated 
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with feeder cells. Two days after transfection, G418 or Puromycin selection was performed to 
the cells (0, 4 mg/ml for G418 and 300 U/ml for Puromycin). 
Clones were visible at around 10 days post antibiotic selection pressure exposure. 
ES cell lines and mouse strains 
Several ES cell lines and mouse strains have been established in our lab for Tet induced 
transgene expression. The cell lines used in this thesis are displayed in Table 5 (Thesis Kruse, 
2013). 
 
Table 5. Transgenic ES cell lines and mouse cells relevant for the thesis. tTA: Tetracycline transactivator protein; 
rtTA: reversed Tetracycline transactivator protein. Uni-directional Tet promoter indicates the synthetic promoter 
consists of 7 tandem operators and a minimal CMV promoter. Bi-directional Tet promoter represents the synthetic 
promoter compromises 1 CMV mini promoter fused to double 7 tandem operators on each flank, which could drive 
2 irrelative genes at the same time in the presence of Doxycycline. GFP is Green fluorescent protein which is 
commonly utilized as reporter gene. HCV replicon denotes the Hepatitis C virus genome without Envelope proteins-
Locus Construct ES cell line Mouse  line Transactivator 
Rosa26 
Bi-directional Tet promoter driving 
luciferase abd GFP 
R26-BiTetGFP- 
ES R26-BiTetGFP 
rtTA under Rosa26 
promoter 
Anti-sense uni-ditrctional Tet 
promoter driving Luciferase-HCV  
R26-
TetHCVasrWT- 
ES 
R26-
TetHCVasrWT 
x Lap-tTA 
rTA from Lap-tTA 
mouse 
Sense uni-ditrctional Tet promoter 
driving Luciferase-HCV 
R26-
TetHCVsWT -
ES 
none rtTA from EF1a promoter 
Sense uni-ditrctional Tet promoter 
driving Luciferase-HCV, flanking 
with cHS4 insulators 
R26-Tet-in-
HCVsWT-ES none 
rtTA from transient 
transfection 
COL1A1 
Sense uni-ditrctional Tet promoter 
driving GFP COL-TetGFP-ES COL-TetGFP 
rtTA under 
ROSA26 promoter 
Sense uni-ditrctional Tet promoter 
driving Luciferase 
COL-Tetlucsr-
ES none 
rtTA under 
ROSA26 promoter 
Sense uni-ditrctional Tet promoter 
driving Luciferase-HCV 
COL-
TetHCVsrWT-
ES 
none rtTA under ROSA26 promoter 
Tigre 
Sense uni-ditrctional Tet promoter 
driving Luciferase 
Tigre-Tetlucs- 
ES none 
rtTA under EF1a 
promoter 
Sense uni-ditrctional Tet promoter 
driving Luciferase-HCV 
Tigre-
TetHCVsWT-ES none 
rtTA under EF1a 
promoter 
8.10 Bi-directional Tet promoter driving luciferase abd rtTA LUC 8.10 LUC 8.10 
rtTA under bi-
directional Tet 
promoter 
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coding part. LUC8.10 mice carry a single integration of Luc3rTA2E (#2375) linearized with PvuI in IB10 (sub-
clone of E14; strain: 129/OlaHsd) ES cells in the Luc8.1 locus. 
 
Cell culture conditions 
 
HEK293T cells, murine R26-Tet-in-HCVasrWT fibroblasts and murine NIH3T3 cells were 
cultured in DMEM (Gibco) medium supplied with 45 ml Fetal Bovine Serum (Sigma), 4.5 ml 
MEM Non-Essential Amino Acids (Gibco), 4.5 ml Penicillin Streptomycin (Gibco), 4.5 ml 
Glutamine (Gibco), 900 µl 2-Mercaptoethanol (Gibco). These cells were in cultivated at 37°C 
with 5% CO2 and 21% O2 at maximal humidity and fed every 3–4 days. Confluent cells were 
passaged into new culture plates or flasks containing fresh media at the ratio of 1:10 to 1:20 
depending on the cell types. For passaging, cells were first washed with PBS and then 
trypsinized for 5 minutes. Afterwards, the trypsinization was inactivated by adding diluted FCS 
containing medium. Then the cells were transferred to a new culture flask or plate containing 
fresh medium. To determine the cell number, an aliquot of the cell suspension was counted. 
Murine G4B12 ES cells, R26-BiTetGFP-ES murine embryonic stems cells, Tigre-TetHCVsrWT-
ES cells and Tigre-Tetlucs-ES cells cell lines were cultured on irradiated mouse embryonic 
fibroblast (MEF) feeder layers in gelatin-coated plates. ES cell culture medium used in this thesis 
was Knockout medium: 400 ml knockout-DMEM, (Invitrogen) supplemented with 75 ml 
knockout serum replacement (Invitrogen), supplemented with 10 ml glutamine (Invitrogen), 5 ml 
nonessential amino acids (Invitrogen), 0.1 mM ß-mercaptoethanol (Sigma), 5 ml sodium 
pyruvate MEM 100 mM (100x, Gibco), 5 ml Penicillin Streptomycin (Gibico), 5 µg/ml insulin, 
1000 U/ml and leukemia inhibitory factor (LIF), 1µl Mitogen-activated protein kinase inhibitor 
(Stemgent) and 3 µl inhibitor of glycogen synthase kinase 3ß (Stemgent). ES cells were 
cultivated at 37°C in a humidified atmosphere with 2% O2 and 7% CO2 and were fed daily. In 
respect to the rapid growing speed these mES cells were passaged every another day to keep 
them at optimal densities to avoid differentiation. During passaging it is critical to trypsinize the 
cells well to ensure a single cell suspension. The passage ratio was kept between 1:6 to 1:10 
depending on the original density and growing speed. Overgrowing will sharply decrease the 
quality of ES cells so it is important to control cells in the middle size to avoid differentiate. 
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Hepatocytes derived from in vitro differentiation from Tigre-TetHCVsrWT-ES cells and Tigre-
Tetlucs-ES cells were cultured in HMM Maintenance Medium (Lonza) in collagen coated plates 
at 37°C in a humidified atmosphere with 5% CO2 and 21% O2. 
Endoderm cells derived from in vitro differentiation from Tigre-TetHCVsrWT--ES cells and 
TigreTetlucs ES cells were cultured in IMDM supplied with 20% FBS (Gibco), 1% Pen/Strep L-
Gln,1% Non-essential aminoacids, 0,2% 50 mM ß-mercaptoethanol and 0,1% 450 mM 
Monothioglycerol (MTG)(Sigma) in collagen coated plates at 37°C in a humidified atmosphere 
with 5% CO2 and 21% O2. 
2.2.1.9	  	  	  	  In	  vitro	  differentiation	  	  
 
In vitro differentiation towards hepatocytes: 
50 x 20 µl drops (each containing 800 ES cells) in mouse ES-cell medium without LIF were 
placed onto the inner side of the lid of a 10cm dish, and the plate was filled with 10 ml of sterile 
PBS. These hanging drops were cultivated for 3-5 days until embryoid bodies (EB) appeared. 25 
EBs were collected and placed onto one gelatinized well of 6-well plate in 2 ml of IMDM. These 
EBs were cultured for 7-10 days and medium were exchanged every another day. Beating 
cardiomyocytes should come up spontaneously after 7 days. The cells were trypsinized with 
500ul trypsin and stopped with 2ml IMDM per well, then transferred to a collagen-coated 6 well 
plate. Medium was changed to HMM next day. The cells were then cultivated for proximally 
20 days in HCM and medium were exchanged every another day until the hepatic like cells 
appeared. 
In vitro differentiation towards fibroblasts: 
50 x 20 µl drops (each containing 800 ES cells) in mouse ES-cell medium without LIF were 
placed onto the inner side of the lid of a 10cm dish, and the plate was filled with 10 ml of sterile 
PBS. These hanging drops were cultivated for 3-5 days until embryoid bodies (EB) were 
appeared. 25 EBs were collected and place them onto one gelatinized well of 6-well in 2 ml of 
DEME. These EBs were then cultivated for proximally 15 days in DEME medium and were fed 
every another day until the fibroblast like cells appeared. 
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2.2.1.10	  	  	  	  Immunostaining	  	  
 
Cells were cultured on cover slips in 12-well plates to 90% confluence. The medium was 
aspirated and the plates were washed 3 times with 2 ml PBS. 1ml/well 4% Paraformaldehyde 
(Sigma) was added for 10 min at R.T. for fixation. Afterwards the plates were rinsed 3 times 
briefly with PBS and the cells were then permeabilized with 0.1% Triton X-100 for 10 min at 
R.T. The plates were then washed 3 times with PBS and permeabilizion was block with 3%BSA 
at 4°C overnight. The next day, primary antibody were diluted in 3% BSA/0.1% Saponin (Sigma) 
solution to appropriate dilution and incubate for 60 min at R.T. (Albumin antibody from Abcam 
(1:1000), Vimentin Antibody from Sigma-Aldrich(1:800)). Then 3% BSA/0.1% Saponin 
solution was added to wash the plates for 3 times. The secondary Ab (1:1000) was then added for 
1h at R.T. At last 3% BSA/0.1% Saponin solution was added to wash th plates for 3 times and 
the coverslips were at last mounted with mounting medium and invert onto glass slides. The 
mounted glass slides were left overnight at R.T. and analyzed the next day. 
 
2.2.1.11	  	  	  	  	  In	  vitro	  luciferase	  expression	  assay	  
 
1 x 105 cells were plated into 6 well plate per well and adhered until 90%-100% density was 
reached. The plates were washed 2 times with 2 ml PBS/well and 500ul 1x RLB buffer (Reporter 
Lysis Buffer, Promega, Cat.# E3971) were added for lysis. The plates were frozen in -80°C for 
10 minutes and thawed on ice. Meanwhile, the illuminometer tubes were filled with 100 µl of the 
Luciferase Assay Reagent. 20 µl supernatant of the cells was applied to the illuminometer tubes 
which were transferred to the illuminometer later. Quantified luminance was related to the total 
amount of protein. Bradford assay (a spectroscopic analytical procedure used to measure the 
concentration of protein in a solution) was used for the analysis (Bradford, 1976). 
 
2.2.1.12	  	  	  	  	  Flow	  cytometry	  
 
1 x 107 cells were resuspended in 500 µl ice-cold FACS buffer (10%FCS in PBS) and re-
suspended thoroughly to guarantee a single-cell suspension form of the cells. Flow cytometry 
(BD FACScalibur, FACSaria, FACScanto) was used to analyze GFP expression (level and 
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population) in transgenic ES cells and sort for TET1c-rtTA positive cells for the further analysis 
analysis. FlowJo 7.6 software was used for the data analysis. 
	  
2.2.1.13	  	  	  	  	  In	  Vitro	  chemical	  treatments	  
 
Murine ES cells were seeded 1 x 105 cells in a 6-well plate. Doxcycline was dissolved in ethanol 
to stocking concentration of 2.5 mg/ml. And the working concentration was 1:1000. Treatment 
was performed at least 24 hours before measurement. Dnmt inhibitors azacytidine (Sigma 
Aldrich) was dissolved in ethanol and added at a final molecular concentration of 1 µM for 
72 hours. Ascorbic acid (Sigma Aldrich) was dissolved in PBS at the concentration of 1 mg/ml. 
1:10 dilution was used in the treatment. Treating time varied accordingly to experiments plan. 
Decitabine (Sigma Aldrich) was dissolved in ethanol and added to the medium at the final 
molecular concentration of 0.5 µM and the treatment was lasted for 48 hours. 
 
2.2.2	  	  	  In	  Vivo	  methods	  
2.2.2.1	  	  	  	  	  Mice	  breeding	  and	  handling	  
 
ROSAGFP mice were generated from murine embryonal stems cells upon targeting the pEM-
rTA2luc3eGFP vector into the Rosa26 locus by RMCE (Sandhu et al. 2013). Luc 8.10 mice were 
generated by random introduction of a single copy of the vector pEM-rTAluc (Pamela Riemer, 
Thesis). The mice were bred in house at the facility of HZI in SPF (specific-pathogen-free) 
conditions. 
All mouse procedures were conducted under local ethical guidelines and after obtaining the 
permissions. 
 
2.2.2.2	  	  	  	  	  Hydrodynamic	  tail	  vein	  injection	  
 
5-12 weeks old ROSAGFP and Luc 8.10 mice were chosen for the experiments. Before injection 
body weight of each mouse has been measured and the tails of the mice were warmed by a 
heating lamp (120W bulb) for 2-5 minutes. When the vein dilated and became more visible the 
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mice were directly placed into the restraint chamber for fixing during the injection. The area was 
swabbed with alcohol and the needle was inserted into the tail vein. 25µg plasmid DNA diluted 
in PBS (1/10 bodyweight ml) were injected for each mouse in 2-5 seconds. 
 
2.2.2.3	  	  	  	  	  In	  vivo	  differentiation	  of	  ES	  cells	  to	  teratoma	  
 
1 x 106 embryonic stem (ES) cells were cultivated on a gelatinized T75 flask without feeder. On 
the day of injection the cells were trypsinized and stopped with ES medium. The cells were then 
centrifuged down at 1000 rpm for 5 min and re-suspended to a cell number of 1*106/100 µl-
1*107/100 µl in ice-cold PBS (cells were kept on ice all the time). Afterwards 100 µl cells were 
injected subcutaneously with a 26 gauge needle on the lower flanks of 8-12-week-old mice on 
the both sides. Mice were sacrificed 5 weeks after injection of the cells to isolate the teratomas.  
 
2.2.2.4	  	  	  	  	  Bioluminescence	  imaging	  with	  Xenogen	  IVIS	  200	  (In	  vivo	  luciferase	  
expression)	  
 
To quantify the luciferase expression level in transgenic mice, Xenogen IVIS 200 Imaging Series 
(Caliper) was used. This system allows using real-time, noninvasive imaging to monitor and 
record cellular activity of luciferase in vivo. Mice for the experiments were anesthetized in the 
built-in anesthetic chamber by 2-2.5% isoflurane (Albrecht). Afterwards each mouse was 
injected with 100 µl of luciferin (30 mg/ml in PBS, Synchem OHG) respectively by 
intraperitoneal (i.p.) injection. Then the mice were transferred to imaging chamber. Standard 
setting was used to detect the luciferase expressing level except the changing of the “field” from 
“C” to “D” and the scanning time prolonged to 5 min. Living image 2.60.1 (Igor Pro 4.09A) 
software was used to analyze images. The photons produced in the subject diffuse through the 
tissues and the IVIS determines this signal at the surface of the subject by means of a sensitive 
photon capturing CCD (charged-coupled device) camera.  
 
2.2.2.5	  	  	  	  	  	  In	  vivo	  chemical	  treatment	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Doxycycline (Sigma): 2 mg/ml; stock: 50 mg/ml in water, kept at 4°C. Doxycycline was 
administered via the drinking water. The water was changed every 3 days. 
Luciferin: 100 µl of 30 mg/ml Luciferin in PBS (Synchem OHG, stored at -70°C) were injected 
i.p.. Images were taken at consecutive time points to cover the time when distribution was 
optimal and the signal the strongest (between 3 and 10 minutes post injection). 
 
2.2.2.6	  	  	  	  	  Histological	  analysis	  
 
Mice were sacrificed and livers were fixed in formalin 4% for 24 hours. Micrograph preparation 
and GFP staining was performed by histopathology facility of HZI. The quantification of GFP 
was determined by counting the number of stained cells by microscopy.
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3   RESULTS  
 
3.1	  	  	  	  	  Evaluation	  of	  Tet	  cassette	  expression	  in	  different	  loci	  
 
Doxycycline induced Tet cassette expression in mice is of high interest. Few integration sites 
have been reported for doxycycline controlled expression with variable success; however, since 
different reporters and/or cassette designs were used, the performance of the individual Tet 
cassettes could not be directly compared. Thus, the first aim of this thesis was to compare three 
particular integration sites for Tet cassette expression in ES cells. The loci were chosen based on 
i.) Previous reports showing doxycycline dependent expression and ii.) Their availability for 
targeted integration by means of Flp mediated recombinase mediated cassette exchange (RMCE). 
The chosen loci are the Rosa26 locus (available for RMCE in RosaAntiluc/G4B12 cells (Sandhu 
et al., 2011), the COL1A1 locus (available for RMCE in KH2 cells (Beard et al., 2006b) and the 
Tigre locus (Zeng et al., 2008) which was made available for RMCE in ES cells by transferring 
the Tigre locus to ES cells (chapter 1.2.2.1 and Wirth et al., umpublished). For the map of these 
loci as well as the details of the targeting procedures see supplementary Figure 1. 
 
3.1.1	  The	  Tigre	  locus	  supports	  best	  expression	  of	  Tet	  driven	  transgene	  expression	  in	  
ES	  cells	  
 
To compare Tet cassette expression in these three loci of embryonic stem cells, a luciferase 
reporter cassette was targeted into the three genomic sites. This reporter cassette comprises the 
luciferase gene, which is expressed from a Tet promoter in a bicistronic unit together with the 
subgenomic HCV replicon (the HCV replicon is not relevant in this study) (Figure 9a-b). For 
targeting the Rosa26 locus and the Tigre locus, the plasmid (TetHCVsWT) encodes a cassette for 
constitutive expression of the rtTA reverse transactivator, which is required to specifically 
activate the Tet promoter in a doxycycline dependent manner. Since KH2 ES cells constitutively 
express rtTA under the control of the Rosa26 promoter, a modified cassette (TetHCVsrWT), that 
comprises an inactivated (reverted) rtTA coding sequence, was targeted in this particular site.  
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Targeting was achieved upon lipofectamine transfection of ES cells. Correctly targeted cells 
were identified by selection for G418 resistance and confirmed by PCR (data not shown). 
According to the site of integration, the ES cell clones were designated as R26-TetHCVsWT-ES, 
Col-TetHCVsrWT-ES and Tigre-TetHCVsWT-ES, respectively (Figure 9A). Individual clones 
of each integration site were propagated and analyzed for the transgene expression level by 
monitoring luciferase activity.  
1x105 cells of each targeted ES cell clone were cultivated with or without doxycycline (2.5 μg/ml) 
for 48 hours. As a positive control, the expression level from the non-integrated (episomal) state 
of the cassette was evaluated. To this end, the wild type ES cells were transiently transfected 
with the TetHCVrWT construct in presence/absence of doxycycline. 48h later, the cells were 
harvested and analyzed for luciferase expression. The luciferase levels were normalized to total 
protein content of the cells.  
 	   	  
 
 
a.) 
b.) 
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Figure 9: Evaluation of three chromosomal loci for the expression of Tet cassette. a.) Schematic depiction of 
the R26-TetHCVs-WT-ES, COL-TetHCVsrWT-ES and Tigre-TetHCVsWT-ES cell clones after targeting. All loci 
were targeted with the luciferase reporter cassette HCV Luc as specified in b). The transactivator in the R26-
TetHCVsWT-ES cell line as well as in the Tigre-TetHCVsWT-ES cell line is encoded by the targeting cassette and 
driven by the EF1α promoter. In the COL-TetHCVsrWT-ES cell clones the transactivator is driven by the Rosa26 
promoter as depicted. b.) Depiction of the luciferase encoding part of HCV genome and fused with luciferase as 
reporter constructs. This construct serves in this study as a luciferase reporter; the HCV part is not relevant for the 
study. c.) Luciferase expression was analyzed in populations of targeted cells as indicated. As control, wild type 
(WT) ES cells were used that do not encode a functional luciferase gene. Briefly, 1 x105 R26-TetHCVsWT-ES cells, 
COL-TetHCVsrWT-ES cells and Tigre-TetHCVsWT-ES cells were seeded on irradiated mouse embryonic 
fibroblast feeder cells in absence and presence of 2.5µg/ml doxycycline for 48h. To evaluate the episomal state, 1 
x105 G4B12 ES cells were seeded on irradiated mouse embryonic fibroblast feeder cells. When the cells reached 90% 
confluence 1µg rtTA expression vector pCMVRTA2HYG and 1µg TetHCVrWT encoding Tet promoter driving 
HCV fused luciferase were co-transfected on these cells in the presence/absence of doxycycline. All the cells were 
harvested 48h after doxycycline addition. Then the cells were harvested and analyzed for luciferase expression. 
Luciferase activity observed in relative light units (RLU) was normalized to µg of total protein present in the cell 
lysate. Error bars indicate standard deviations calculated from 3 independent samples. 
Figure 9c shows the evaluation of the luciferase reporter construct in the different loci. In 
presence of doxycycline, high luciferase expression of 1 x105 RLU/µg was observed for 
c.) 
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TetHCVrWT episomal expression. In contrast, about 80-fold less expression was observed in 
absence of doxycycline which confirms that the construct was functional. However, neither basal 
expression nor doxycycline-mediated induction was observed when this Tet cassette was 
integrated into the Rosa26 locus. In the COL1A1 locus, in presence of doxycycline very low 
expression (8 x101 RLU/µg) was detectable with a fold induction of 2 compared to the non-
treated cells. For the Tigre locus, basal levels were found to be elevated to 200 RLU/µg and 
8-fold inducibility was reached upon cultivation in doxycycline containing media. Importantly, 
in presence of doxycycline 20- and 100-fold higher luciferase expression was detected for the 
Tigre locus comparing to the COL1A1 locus and the Rosa26 locus, respectively. However, in 
none of these loci the cassette could reach the expression level of the episomal state. As shown in 
Figure 9c, 10-fold more luciferase expression was observed in the episomal state compared to 
the expression level in the Tigre locus upon targeting. Together, this indicates that specific 
silencing of the Tet cassettes occurred after genomic integration into all three loci, although this 
occurred to different extent. 
To rule out the possibility that the rtTA level driven by the EF1α promoter is not sufficient to 
induce the Tet promoter upon single copy integration by targeting, rtTA was additionally 
provided by transient transfection of the vector pCMVRTA2HYG. In this vector the CMV 
promoter controls the expression of rtTA. However, the overexpression of rtTA in R26-
TetHCVs-WT-ES, COL-TetHCVsrWT-ES and Tigre-TetHCVsWT-ES cells did not result in 
increased expression levels of luciferase (data not shown). Thus, the expression level of rtTA is 
not the reason for the low expression of Tet cassettes after chromosomal integration.  
To sum it up, even though in the episomal state proper expression and regulation of luciferase 
was observed, the expression dramatically dropped upon integration of the Tet cassettes in all 
three investigated chromosomal sites. Of note, out of the three investigated loci, the Tet cassette 
performed best in the Tigre locus. 
 
3.1.2	  Single	  cell	  analysis	  shows	  heterogenous	  expression	  in	  the	  Rosa26	  locus	  and	  in	  
the	  COL1A1	  locus	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To further characterize the downregulation of expression upon chromosomal integration it was 
investigated whether the low expression was the result of low but homogenous expression levels 
in individual cells or the fact that a few cells in the population expressed high levels of luciferase 
while others were completely silenced. For this purpose a GFP reporter Tet cassette was 
integrated into the Rosa26 and the COL1A1 locus by RMCE. In contrast to luciferase, which is 
measured in the cell lysates and which allows to detect transgene expression in populations of 
cells, GFP allows a cell specific analysis of expression. The targeted ES cell clones were 
identified by PCR. The targeted transgenic ES cell lines (designated as R26-BiTetGFP ES and 
Col-TetGFP) were treated for 48h with or without doxycycline. GFP expression was analyzed by 
flow cytometry. In both cell lines, rtTA was expressed by the endogeneous Rosa26 promoter.  
In Figure 10b, the expression profiles of representative cell populations are depicted. In absence 
of doxycycline, a small fraction of the two isogenic cell populations showed GFP expression (0.4% 
for the Rosa26 and and 3% for the COL1A1 locus). Interestingly, upon treatment with 
doxycycline, a fraction of cells from cell lines both showed GFP expression (2.6% for Rosa26 
and 15.7 % for COL1A1 locus). Of note, the majority of cells do not express GFP after treatment 
with doxycycline. In Figure 10c, data are summarized for three populations per clone. In the Col-
TetGFP ES cell line, a total of 15% of cells exhibited GFP expression after doxycycline 
induction. This corresponds to a moderate induction level (5-fold). In contrast, only 2.6% of the 
R26-BiTetGFP ES cells showed GFP signal after induction with doxycycline, which was 5-fold 
less compared to the Col-TetGFP ES cells. These data indicate that the cells were highly 
heterogeneous with respect to the expression and only a small fraction was in the active state 
after treatment with doxycycline.  
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a.) 
b.) 
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Figure 10: Heterogeneous GFP expression from the Tet promoter in mouse ES cells. a.) Depiction of the Tet 
cassettes integrated in R26-BiTetGFP ES cells or Col-TetGFP ES cells. The construct integrated into the R26-
BiTetGFP ES cells carried both the luciferase and the GFP under a bi-directional Tet promoter, while the rtTA was 
expressed by the endogeneous Rosa 26 promoter. A similar construct was integrated into the Col-TetGFP ES cells 
carrying the uni-directional Tet promoter driving GFP in the COL1A1 locus and the transactivator rtTA was 
expressed by the endogenous Rosa26 promoter. b-c.) 1 x105 Col-TetGFP ES cells or R26-BiTetGFP ES cells were 
seeded on the irradiated mouse embryonic fibroblast feeder cells in absence and presence of 2.5 µg/ml doxycycline 
for 48h. Then the cells were harvested and analyzed for GFP expression by FACS. Data were analysed by FLOWJO 
(FLOWJO; LLC). Representative plots are depicted. c.) Data are shown for three populations per clone. Error bars 
indicate standard deviations. 
 
To sum up the findings, COL1A1 locus and Tigre locus supported better Tet cassettes expression 
in ES cells compared to Rosa26 locus. However, the achieved expression levels were still low. 
Of note, single cell GFP expression analysis showed that the overall low expression of the Tet 
cassettes upon integration was the result of a heterogenous expression within the targeted 
population of cells. Only a small fraction of cells expressed GFP while the other cells seemed to 
be completely silenced.  
 
3.1.3	  Silencing	  of	  Tet	  cassette	  in	  COL1A1	  locus	  and	  Tigre	  locus	  upon	  differentiation	  
 
To investigate whether the expression of the Tet cassettes could be maintained upon embryonic 
differentiation, transgenic mice were generated from Col-TetGFP ES cells and R26-BiTetGFP 
ES cells, respectively. They were analyzed for GFP expression by RT-PCR. For this purpose 
c.) 
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animals from both strains were fed with doxycycline in the drinking water. The mice were 
sacrificed and the liver and the spleen were harvested for RNA extraction. However, no GFP 
expression was detectable in the samples of R26-BiTetGFP and Col-TetGFP transgenic mice 
(data not shown). 
Since transgenic mice were not available for the Tigre ES cells, in vitro differentiation was 
followed to mimic embryonic development and to investigate the behavior of Tet cassettes in the 
Tigre locus. For this purpose, a differentiation protocol was used that induces differentiation 
upon withdrawal of the stem cell factor LIF and embryonic body formation by using hanging 
drops. Then, the cells, in embryonic bodies, were exposed to medium that supports the 
differentiation into the endodermal lineage and finally a hepatocyte-like state (for details of the 
protocol see chapter 2.2.1.9). Expression was analyzed at different stages of differentiation: in 
embryonic bodies and in the finally differentiated state.  
To investigate the expression upon differentiation, ES cells were targeted with two different 
constructs. On the one hand the Tigre-TetHCVsWT ES cell clones were used. On the other hand 
a similar luciferase expression construct (Tetlucs), optimized for luciferase expression by 
elimination of HCV elements, was specifically targeted into the Tigre locus. These cells are 
designated as Tigre-TetlucS ES cells. For each cassette various clones were established. 
In Figure 11b a scheme of the differentiation protocol and representative pictures of the cells at 
the various differentiation stages are shown. In particular, the changes of the morphology from 
ES cells (Figure 11b-A) via embryonic bodies (Figure 11b-B) and endodermal lineage (Figure 
11b-C) to the hepatocyte-like cells (Figure 11b-D) can be observed. In this terminally 
differentiated stage, a typical hepatocyte-like phenotype was observed, characterized by distinct 
nuclei and a confluent monolayer (Figure 11b-D). The hepatic phenotype of the differentiated 
cells was confirmed by albumin staining by immunocytochemistry (Figure 11b-E). 
From all stages aliquots of cells were exposed to doxycycline for 48 hours and luciferase 
expression was analyzed. 
All the ES clones showed an inducible expression for both of the cassettes. This is exemplified 
by the ES clone Tigre-TetlucS 2-5 and the Tigre-TetHCVsWT-ES clone 3-1 in Figure 11. As 
expected from the different design, the Tigre-TetlucS cells showed about 10-fold increased 
levels of expression upon doxycycline treatment. Interestingly, upon formation of embryonic 
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bodies and in terminally differentiated hepatocytes expression was found to be diminished or 
completely lost for both cassettes.  
These data indicate that although the Tigre locus supports a good expression of Tet cassettes in 
ES cells, the expression of Tet cassette is lost after differentiation. This suggests that also in this 
integration site the Tet cassette is silenced after differentiation. 
 
  
 
 
  
 
                                                                                                        
a.) 
b.) 
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Figure 11: Tet controlled Luciferase expression in the Tigre locus upon in vitro differentiation. a.) The design 
of the cassettes integrated in the Tigre-Tetlucs-ES clone2-5 and Tigre-TetHCVsWT-ES clone3-1 is depicted. Tigre-
Tetlucs ES cells contain luciferase. The expression is controlled by the Tet promoter. In contrast the Tigre-
TetHCVsWT-ES cells comprise a HCV luc reporter driven by the Tet promoter. Both cassettes are integrated into 
the Tigre locus. b.) Procedures for in vitro differentiation: 50 x 20 µl drops (each containing 800 Tigre-TetlucS-ES 
cells or Tigre-TetHCVsWT-ES cells) in mouse ES cell medium without LIF were placed onto the inner side of the 
lid of a 10cm dish, and the plate was filled with 10 ml of sterile PBS. The hanging drops were cultivated for 3-5 
days until embryoid bodies (EB) appeared. A representative picture is shown (B). 25 EBs were collected, dissociated 
and plated in 2 ml of IMDM on one gelatinized well of a 6-well plate to achieve the endoderm stage (C). Beating 
cardiomyocytes came up spontaneously after 7-10 days (not shown). Then, the cells were transferred to a collagen 
coated 6-well. Medium was shifted to HGM (hepatocytes growth medium) next day. The transformation of cell 
morphology was closely monitored every day. After proximally 20 days in HGM, hepatic like cells appeared (D). 
The phenotype of the hepatic like cells was confirmed by immunostaining of hepatic marker albumin (red), nuclei 
were stained with DAPI (blue) (Figure a-E). For comparison, a picture of ES cells is shown (A). c.) Luciferase 
activity was detected in relative light units (RLU) and normalized to µg of total protein present in the cell lysate. 
Error bars indicate standard deviation from 3 independent samples of a particular cell clone. For each construct, 
results from one out of five tested clones are depicted. 
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3.2	  Transgene	  silencing	  can	  be	  rescued	  upon	  treatment	  with	  epigenetic	  
modifiers	  	  
 
Previous data showed that the Tet cassettes were expressed to a moderate extent in the Tigre 
locus in ES cells but they were silenced upon in vitro differentiation. To investigate the 
mechanism of transgene silencing, epigenetic modifiers were used to rescue the expression. To 
this end, Aza was used to treat the cells during the whole period of differentiation. Aza is a 
demethylation reagent that specifically prevents the action of the DNA de novo methylase 
DNMT1 (chapter 1.2.1.2).  
The two different ES cell clones, Tigre-TetHCVsWT-ES clone 3-1 and Tigre-TetlucS-ES 
clone 2-5, were analyzed. To monitor the effect of Aza on the differentiation, untreated ES cells 
were differentiated in parallel. Both conditions, with or without Aza treatment led to the 
formation of embryoid bodies as well as differentiation into the hepatocyte-like stage. However, 
Aza treated group showed an altered morphology characterized by a rough surface of embryoid 
bodies compared to the untreated group. Moreover, longer differentiation times and a reduced 
efficiency of hepatic differentiation were observed in the Aza treated group. Lineage specific 
differentiation into hepatocyte-like cells was confirmed by staining for albumin expression 
(Figure 12a-C, D and G, H). 
Interestingly, while the expression of luciferase was silenced in Aza-free control sampleswhich 
correlates with previous data (compare chapter 3.1.3), in presence of Aza both ES cell clones 
maintained the respective luciferase expression level during differentiation. This was verified for 
the embryoid body cells as well as in the hepatocyte-like cells. TheAza treated group of the 
Tigre-TetHCVsWT-ES clone 3-1, exhibited 6-fold and 20-fold more expression at EB stage and 
hepatic stage, respectively, compared to the untreated group. Similarly, Tigre-Tetlucs-ES clone 
2-5 also showed a 30-fold and 8-fold higher expression level in the Aza treated group than in 
theuntreated group at EB and hepatic stage, respectively (Figure 12b). Overall, compared to the 
embryonic state the expression level could be partially maintaind during differentiation of the 
Tigre-Tetlucs-ES clone2-5 cells. Interestingly, the luciferase induction was even increased in the 
differentiated Tigre-TetHCVsWT-ES clone 3-1 at the hepatocyte-like differentiation stage 
(Figure 12 b).	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In summary, the silencing of the Tet cassette during in vitro differentiation could be at least 
partially rescued by Aza treatment. This implies that the silencing of the Tet promoter upon 
integration into the Tigre locus might be the consequence of DNA methylation of the Tet 
promoter during differentiation and can be overcome by blocking its methylation. 
	   	  
 
 
a.) 
b.) 
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Figure 12: Expression level of Tet cassette in the Tigre locus upon in vitro differentiation to hepatic like cells 
in presence of 5-azacytidine. a.) Morpology of Aza untreated/treated samples during differentiation according to 
the protocol specified in chapter 2.2.1.9. b.) Luciferase expression levels during the differention. For the Aza treated 
group, Aza was present during the whole procedure. 2.5 µg/ml doxycycline was present/absent during the whole 
procedure. Luciferase activity observed in relative light units (RLU) was normalized to µg of total protein present in 
the cell lysate. Error bars indicate standard deviation from 3 independent samples. 
 
 
3.3	  Silencing	  of	  the	  Tet	  cassettes	  can	  be	  partially	  overcome	  by	  chromosomal	  
insulators	  
  
3.3.1	  	  	  	  Insulated	  construct	  expression	  in	  ES	  cells	  in	  Rosa26	  locus	  
 
The results from the previous chapters suggest that the Tet promoter is epigenetically modulated 
upon integration into the three chromosomal sites. To shield the Tet promoter from the 
influences of the flanking chromatin, chromosal insulators were introduced into the targeting 
cassette. Chromosal insulators are described to prevent transgene silencing against the impacts 
from the genomic context by shielding the cassette. The best characterized insulator is the 1.2kb 
spanning cHS4 element, a vertebrate insulator element derived from the chicken β-like globin 
gene cluster (Majocchi, Aritonovska, & Mermod, 2014; Rincón-Arano, Furlan-Magaril, & 
Recillas-Targa, 2007; Sharma et al., 2012; Sinn, Burnight, Hickey, Gary, & Mccray, 2005). 
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Various combinations have been tested. For optimal shielding, it has been shown that two copies 
of cHS4 full length elements need to be introduced 5’ and 3’ of the cassette of interest (ekkali et 
al., 2008; Bell et al., 1999; Burgess-Beusse et al., 2002; Recillas-Targa et al., 2002). Accordingly, 
two copies of the full length cHS4 element were incorporated into the vector TetHCVrsWT to 
flank the Tet cassette (Figure 13a).  
Since the expression of the Tet cassette was the weakest in the Rosa26 locus, this locus was 
chosen to test the modified Tet construct. Thus, the modified construct was targeted into the 
Rosa26 locus in ES cells by RMCE. Clones (designated as R26-Tet-in-HCVsWT-ES) were 
established and confirmed by PCR.  
Upon analyzing 13 isogenic R26-Tet-in-HCVsWT-ES clones with respect to the expression level 
in presence/absence of doxycycline, four different expression profiles were observed.  
Profile 1 as represented by R26-Tet-in-HCVsWT-ES CL5' exhibited a 60-80 -fold higher 
expression than the uninsulated ones (Figure 13 b). At the same time, a weak induction of only 2 
was observed. This profile was found in 2 out of 13 clones. 
4 out of 13 clones are classified to profile 2. This profile is displaying a better induction of 
luciferase expression upon doxycycline treatment than clones of profile 1. For instance, R26-Tet-
in-HCVsWT-ES CL3' achieved 6-fold increase in luciferase expression upon doxycycline 
treatment however the expression level after induction is lower than that from profile 1. 
Of note, 6 out of 13 clones were classified into profile 3. These clones showed neither elevated 
basal expression nor any induction compared to the non-insulator clones. This is exemplified by 
R26-Tet-in-HCVsWT-ES CL1' and CL4'.  
Moreover, one clone was identified (clone2’) which showed higher basal expression but no 
induction. This phenotype is classified as profile 4.  
Importantly, the expression phenotype of the four groups of clones was stable upon passaging 
for > 10 passages (data not shown). 
Altogether, regulated expression could be achieved in various clones by flanking the Tet 
cassettes with two copies of the cHS4 insulator. However, the heterogenous expression in the 
various clones was unexpected since all the clones were genetically identical (isogenic) as a 
result of the targeted integration by RMCE. Still, a variation from clone to clone was observed. 
This suggests that random silencing processes occured during targeting and resulted in a 
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pronounced stochasticity. In conclusion, the cHS4 insulators can only partially overcome 
silencing. 
 
                                     
 
 
 
Figure 13: Tet-dependent luciferase expression level of ES clones within the Rosa locus with or without cHS4 
insulator. a.) 2 copies of the cHS4 chromosomal insulator were introduced in TetHCVrsWT construct before the 
Tet promoter and after the HCV luc replicon. The insulated construct was then targeted into Rosa26 locus by RMCE 
and the R26-Tet-in-HCVsWT-ES cell clones were isolated. The design of the expression cassette is depicted. b.) 
a.) 
b.) 
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Individual R26-Tet-in-HCVsWT-ES clones were tested for luciferase expression after targeting. Five R26-Tet-in-
HCVsWT-ES clones were selected. For comparison, four TetHCVrsWT-ES clones without insulators were analysed. 
2.5µg/ml doxycycline was/was not administrated for 48h. rtTA was provided by transient transfection of 
pCMVRTA2HYG(P2288) 48 hours before the cells were harvested. Luciferase activity observed in relative light 
units (RLU) was normalized to µg of total protein present in the cell lysate. Error bars indicate standard deviation 
from 3 independent samples.  
 
3.3.2	  	  	  	  Expression	  stability	  of	  insulated	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To investigate the stability of expression profiles of R26-Tet-in-HCVsWT-ES clones upon 
differentiation, the insulated clones R26-Tet-in-HCVsWT-ES clone 3’ and 5’ (representing 
profile 1 and 2, respectively) were differentiated to the hepatic lineage according to the protocol 
described in chapter 2.2.1.9. Representative pictures of the cells upon differentiation are shown 
in Figure 14a.  
The expression status was again monitored at EB stage and upon differentiation to the hepatic 
lineage. Of note, irrespective of the differentiation stage (EB or hepatocyte-like stage), both of 
the insulated clones maintained the luciferase expression according to the profile presented in ES 
cells: in the hepatic state, clone 5’ maintained a high basal level and low inducibility while clone 
3’ showed low basal level and high inducibility. In contrast, the non-insulated cells that were 
differentiated in parallel were silenced. This is in agreement with the previous data (chapter 
3.3.1). Thus, in clones 3’ and 5’, the insulator elements could provide shielding of Tet cassette 
from silencing upon hepatic differentiation (Figure 14b and 14c).  
To clarify whether the anti-silencing ability of cHS4 insulator was cell-type dependent the cells 
were also differentiated into fibroblasts. For this purpose, the embryonic bodies were seeded on 
un-gelatinized plates and cultivated in 5+ DMEM fibroblast medium (Figure 14a). Ten days later, 
the morphology of cells changed to fibroblastic phenotype(Togo et al., 2011). Cells were seeded 
in presence and absence of doxycycline and analyzed for luciferase expression. Interestingly, the 
two clones behaved differently. As demonstrated in Figure 14b-c, clone 3’ kept luciferase 
expression upon fibroblast differentiation. In contrast, clone 5’ showed a 10-fold reduction in 
luciferase expression upon fibroblast differentiation which was found to be associated with a 
reduced inducibility.  
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Figure 14: Expression pattern of the insulated Tet cassette in the Rosa26 locus upon in vitro differentiation. 
a.) Cells targeted with insulated Tet cassettes as depicted in Figure 14 were subjected to in vitro hepatic 
differentiation as detailed in chapter 3.1.3. The hepatic phenotype was confirmed by both morphology and 
immunocytochemistry for albumin (Figure a-E, red fluorescence). For differentiation to fibroblasts, 25 EBs were 
seeded on an un-gelatinized well of a 6-well plate in 2 ml of 5+DMEM medium. 10 days after plating most of the 
cell differentiated spontaneously to fibroblast-like cells. Immuncytochemistry for vimentin was followed to confirm 
fibroblastoid state (red) (Figure a-G). Cells were maintained in presence/absence of 2.5 µg/ml Doxycycline during 
the whole procedure. rtTA was provided by transient transfection of pCMVRTA2HYG(P2288) two days before the 
cells were harvested. Luciferase activity observed in relative light units (RLU) was normalized to µg of total protein 
present in the cell lysate. Expression level of R26-Tet-in-HCVsWT-ES clone 3 (b) and R26-Tet-in-HCVsWT-ES 
clone 5 (c) upon differentiation to the various differentiation states is shown. Error bars indicate standard deviations 
from 3 independent samples. 
 
Since a change in regulated expression of the Tet cassette was not found upon in vitro 
differentiation into the hepatic but into the fibroblastic state, the cells were checked upon 
differentiation into the various tissues in vivo. For this purpose, clone3’ and clone5’ were 
subjected for teratoma formation upon subcutaneous injection. A teratoma is a kind of 
nonmalignant tumor that comprises a disorganized mixture of cells and small foci of tissue 
containing cells from all three germ-layers: ectoderm, mesoderm, and endoderm. This feature 
makes it a frequently used model to simulate embryonic development in vivo. 
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For teratoma formation, 106-107 cells of R26-Tet-in-HCVsWT-ES clone 3’ or clone 5’ ES cells 
were injected subcutaneously to the lower flanks of 8-12-week-old RAG-/- mice. 3-4 weeks after 
injection teratomas were visible. The mice were sacrificed to isolate teratomas. The teratomas 
were minced and cells were expanded in vitro. The cells were cultivated in presence/absence of 
doxycycline and transfected with pCMVRTA2HYG (Nr.2288) encoding for the transactivator 
rtTA. 48h later, the luciferase level was measured.  
Interestingly, clone 3’ maintained inducible luciferase expression at the stage of teratoma 
although the basal level slightly increased compared to the non-differentiated ES cell state. These 
results are in line with the inducible expression of luciferase upon in vitro differentiation. In 
contrast, expression in clone 5’ was reduced to the basal expression level and could not be 
induced by doxycycline upon in vivo differentiation (Figure 15b). 
To sum it up, cHS4 insulator could partially rescue Tet cassette expression in the Rosa26 locus 
in ES cells upon differentiation in vitro and in vivo. However, a pronouned clonal variation was 
observed. The data indicates that the cHS4 modification is not robust enough to protect the Tet 
promoter.  
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Figure 15: Expression level of the insulated Tet cassette in the Rosa26 locus in teratoma derived cells. a.) For 
in vivo differentiation, 1x106-107/ 100 µl R26-Tet-in-HCVsWT-ES clone 3’ or clone 5’ were injected 
subcutaneously to the lower flanks of 8-12-week-old RAG-/- mice on the both sides, respectively. Teratomas were 
visible 4 weeks after injection and mice were sacrificed to isolate teratomas. Each teratoma was minced and was 
cultivated seperately for about 7 days on one well of a gelatinized 6 well plate. Different cell types were observed 
from the teratoma-derived cells as exemplified by the pictures (fibroblast-like cells, vascular smooth muscle like cell, 
hepatocyte-like cells and neuron-like cells are shown). b.) To evaluate expression, the cells were transfected with 
2 µg rtTA expression plasmid pCMVRTA2HYG in the presence/absence of doxycycline. All the cells were 
harvested 48h after doxycycline treatment. Luciferase activity observed in relative light units (RLU) was normalized 
to µg of total protein present in the cell lysate. Error bars indicate standard deviations from 3 independent samples. 
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The results of chapter 3.2 and 3.3 suggest that the Tet cassettes are prone to epigenetic silencing 
upon differentiation. The fact that expression could be at least partially rescued by Aza/cHS4 
insulator suggests that silencing might be dependent on DNA methylation. 
However, since neither the targeting into different chromosomal integration sites nor the flanking 
of the Tet cassette by cHS4 elements could fully/efficiently overcome the silencing of the 
cassettes, it was aimed at specifically modulating the epigenetic status of the Tet promoter by 
impairing or reducing its methylation. 
For this purpose the TET methylcytosine dioxygenase 1 protein (TET1c) was exploited. This 
protein possesses enzymatic activity capable of hydroxylating 5mC to generate 5hmC which is 
then further processed and finally demethylated to unmethylated cytosine (chapter 1.2.1.2). To 
specifically target this enzymatic activity to the Tet promoter sequence, the catalytic domain of 
TET1 (TET1c) was fused to the bipartite rtTA, which encodes both a binding domain 
specifically for the operator sequences of the Tet promoter and an activation domain for active 
transcription (VP16). A tripartite fusion gene was cloned comprising the catalytic domains of 
TET1, the transactivating domain as well as the specific binding domain of rtTA (for details of 
the cloning see methods chapter 2.2.1.3). The vector encoding this tripartite fusion protein was 
designated as TET1c-rtTA and drives expression by the CMV promoter.  
Further, a control plasmid encoding the truncated protein TET1c-U was established. TET1c-U 
carries only the catalytic domain of TET1c-U without any domain for specific DNA binding. 
The design of the vectors used in this study is shown in Figure 16.	  	  
 
 
Figure 16:  Schematic representation of the expression constructs for targeted demethylation. rtTA: This 
construct comprises the full length of bipartite rtTA including the domain (BD/core) for binding the operator regions 
a.)  
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from Tet promoter as well as the activation domain (AD) for transcriptional activation. TET1: parental expression 
construct encoding the full length native TET1 comprising both the DNA binding domain and the catalytic domain. 
In the tripartite Tet1c-rtTA the rtTA was combined with the catalytic domain of TET1 (TET1c). TET1c-U: Tet1c-U 
has only with the catalytic domain of TET1 (TET1c). In all the vectors, expression of the respective genes is 
controlled by the CMV promoter.  
 
First, the functionality of the transactivating domain of the tripartite fusion protein TET1c-rtTA 
was investigated. For this purpose, 293T cells were transiently transfected with a vector 
encoding TET1c-rtTA and the reporter plasmid Tetlucsr (Tet promoter driving luciferase 
expression). Upon 2 days in presence or absence of doxycycline the cells were harvested and 
analyzed for luciferase expression. As a positive control a plasmid carrying the unmodified 
transactivator (rtTA) was cotransfected with the same reporter plasmid under the same 
conditions. 
As shown in Figure 17, co-expression of the tripartite fusion protein TET1c-rtTA could support 
doxycycline dependent expression the reporter. While in absence of doxycycline the expression 
levels were comparable, addition of doxycycline increased expression of the reporter. Together, 
these data indicate that TET1c-rtTA fusion protein can support Tet-inducible expression, 
confirming that the transactivator domain is not compromised in the tripartite fusion protein. 
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Figure 17: Transactivation potential of TET1c-rtTA in 293T cells. 24 hours after seeding, 1x105 HEK 293T cells 
were seeded per 6 well, transient co-transfections were conducted. 1 µg Tetlucsr luciferase expression reporter 
plasmid was cotransfected with either 1 µg rtTA expression (pCMVRTA2HYG,) vector or 1 µg of TET1c-rtTA. 
Cells were harvested 48 hours after 2.5 µg/ml doxycycline treatment. Luciferase activity of cell lysates was 
measured. Relative light units (RLU) were normalized to µg of total protein present in the cell lysate. Error bars 
indicate standard deviation from 3 independent samples. 
 
To evaluate the demethylation capacity of TET1c-rtTA, it was evaluated if the tripartite fusion 
protein can reactivate silenced Tet cassettes. To this end, R26-BiTetGFP ES cells were analyzed 
for GFP expression upon transient transfection of the TET1c-rtTA plasmid. rtTA was transfected 
as a control. Further, Tet1c-U was transfected which lacks a specific DNA binding domain. As a 
positive control, the cells were treated with the chemical inhibitor of methylation decitabine (5-
aza-2'-deoxycytidine). All cells were incubated with or without doxycycline for 72 hours. 
In agreement with the data shown in chapter 3.1.2, the low numbers of GFP expressing R26-
BiTetGFP ES cells only increased slightly in presence of DNMT inhibitor – in this case 
Decitabine. However, a pronounced increase of GFP expression was observed upon transfection 
of the tripartite fusion gene TET1c-rtTA. A population of GFP positive cells (22%) was 
observed in the TET1c-rtTA transfected sample while the basal expression was not significantly 
higher compared to the other analyzed samples (see Figure 18b for representative samples and 
Figure 18c for the summary of 3 independent samples per clone). Of note, transfection of rtTA 
alone did not increase the number of expressing cells dramatically. These data show that TET1c-
rtTA can clearlyactivate Tet cassette in the Rosa 26 locus. This suggests that the demethylation 
domain can improve expression in these cells. Interestingly, also the TET1c-U transfected cells 
showed a clear GFP fraction in the induced state of around 16%. This suggests that a certain 
reactivation of Tet driven GFP was achieved also in these ES cell clones. 
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Figure 18:  TET1c-rtTA induced GFP reactivation in ES cells in Rosa26 locus.  a.) Depiction of the Tet 
construct within R26-BiTetGFP ES cell. This cell line encodes a bi-directional Tet promoter driving GFP and 
luciferase in the Rosa26 locus while the transactivator rtTA is provided by the endogenous Rosa26 promoter. b.-c.)1 
x105 R26-BiTetGFP ES clone7 cells per 6 well were seeded on irradiated mouse embryonic fibroblast feeder cells. 
48 hours after seeding ES cells were treated as follows. Untreated: non-transfected cells; + DEC: incubation with 0.5 
µM decitibine for 48 hours; rtTA: transfection with 2 µg rtTA expression vector (pCMVRTA2HYG); Tet-1U: 
transfection with 2µg TET1c-U; TETc-rtTA transfection with 2µg TET1c-rtTA plasmid. Samples were cultivated 
for 72 hours in presence or absence of doxycycline as indicated. GFP positive cells were analyzed by flow 
cytometry and data were analyzed by FLOWJO (FLOWJO; LLC). Representative FACS plots are shown in b) and 
mean expression from 3 independent samples is presented in c). Error bars indicate standard deviation from three 
samples. 
 
It was investigated if the construct could also rescue the transgene expression in the Tigre locus. 
Thus, TigreR26-TetHCVsWT-ES cell clone 2-5 and clone 3-1, as well as TigreTetlucs ES clone 
4-1, and clone 1-3 (as described in chapter 3.1.3) were transiently transfected with the TET1c-
rtTA or treated with the demethylating agent Aza according to the procedure described above. 
Aza treatment could re-activate expression only in the TigreR26-TetHCVsWT-ES clone 3-1 and 
TigreTetlucs ES clone 1-3 while in the other clones expression was not changed by Aza.  
Interestingly, transfection of Tet1c-rtTA similarly showed clear expression of GFP in the same 
two clones while no reactivation could be achieved in the other two. Indeed, all clones which 
could react to Aza showed also an increased expression of luciferase upon TET1c-rtTA 
transfection, while other clones could not react to both (Figure 19a-b).  Thus, this suggests that 
Aza as well as TET1c-rtTA mediated reversion of silencing can only be achieved in certain 
cells/cell states while others are resistant to these treatments.  
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Figure 19: TET1c-rtTA induced reactivation of luciferase in ES cells in the Tigre locus. Tigre-Tetlucs ES 
clone4-1 and 1-3 as well as Tigre-TetHCVsWT-ES clone 2-5 and 3-1 were used in this experiment. The design of 
the constructs is indicated. Tigre-TetHCVsWT-ES encode the HCV luc reporter while Tigre-Tetlucs ES cells have 
the Tetluc reporter. Both constructs carry the Tet promoter driving luciferase in Tigre locus while the transactivator 
rtTA was expressed from the EF1α promoter from the same targeting construct. 1 x105 cells of each clone were 
seeded on the irradiated mouse embryonic fibroblast feeder cells in gelatinized 6 wells. 48 hours after seeding the 
ES cells they were treated with the following conditions: DOX-: inoculated without Doxycycline for 72 hours; 
DOX+: inoculated with 2.5 µg/ml doxycycline for 72 hours; DOX+AZA+: inoculated with 2.5 µg/ml doxycycline 
and 1 µM/ml Aza for 72 hours; DOX+ (TET1c-rtTA)+: transfected with 2 µg TET1c-rtTA plasmid transiently and 
incubated with doxycycline for 72 hours. Luciferase activity observed in relative light units (RLU) was normalized 
to µg of total protein present in the cell lysate. Error bars indicate standard deviation from 3 independent samples 
and significance was calculated using online P value calculator. 
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Finally, also the COL1A1 locus were analyzed for the responsivenes to TET1c-rtTA. However, 
for this locus only ES cell clones were isolated that were resistant to Aza treatment. In agreement 
with the observation for the Tigre locus, all the clones also failed to respond to TET1c-rtTA 
(data not shown). 
To sum it up, rescuing of the Tet cassette expression by TET1c-rtTA could be observed in two 
different loci (Rosa26 and Tigre) and could be demonstrated for several cassette designs. 
Interestingly, some clones did not respond. Of note, the non-responding clones were also 
resistant to chemical activation by Aza. This might indicate that the states of silencing are 
different in these clones. For a more detailed discussion of this observation please see chapter 
4.3.1.  
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The in vitro investigation of the tripartite TET1c-rtTA fusion protein showed efficient rescue of 
the Tet cassette expression in targeted ES cells which was comparable to or even better than the 
treatment with chemical demethylation reagents (Figure 18-19). To investigate the role of the 
potential of TET1c-rtTA fusion protein in vivo, this protein was expressed in several transgenic 
animals. Since it was shown that the R26-BiTetGFP ES cell clone could be reactivated by the 
Tet1c rtTA construct in vitro the corresponding R26-BiTetGFP transgenic mouse line was used 
(see Figure 20a for cassette design).  
To deliver the TET1c-rtTA plasmids to the mouse, the plasmids were injected by hydrodynamic 
tail vein (HDTV) injection. This method gives rise to gene transfer preferentially in the liver of 
the mice (chapter 2.2.1.3). Briefly, 25 µg of the plasmid DNA was diluted in 0.1% NaCl at the 
volume of 10% of the body weight of the animal. This volume was injected within 10 seconds 
into the tail vein. Injection was done both in untreated mice and mice preconditioned by a 7 day 
feeding with doxycycline. Luciferase expression was monitored by in vivo bioluminescence 
imaging using the IVIS machine.  
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TET1c-rtTA, the rtTA, the TET1c-U as well as a plasmid free PBS control were 
hydrodynamically injected. The results of the expression analysis 36 hours after injection are 
shown in Figure 20c. Of note, TET1c-rtTA injected mice exhibited a remarkable increase of 
luminescence signal. This increase in expression was only obtained in the doxycycline induced 
group of animals but not in the un-induced animals (data not shown). In contrast, none of the 
injections with rtTA, TET1c-U or PBS as controls showed significant rise of luciferase 
expression regardless of doxycycline induction. This suggests that TET1c-rtTA, but not the 
unspecific control TET1c-U or the rtTA alone can reactivate expression. 
To evaluate whether the liver cells homogenously or heterogeneously activated transgene 
expression, the specific increase in transgene expression was analyzed by histology on cellular 
level. Therefore, 36 h after HDTV injection/delivery of the plasmid mice were sacrified and liver 
samples were collected analyzed for GFP expression. In the liver of non-treated or mock-treated 
animals, only very few GFP positive cells were identified (about 1 cell per view or 0.89% of 
cells). A clearly increased number of GFP positive cells were observed in TET1c-rtTA mice. 
Quantification by counting the number of GFP positive cells per view revealed that about 16 
GFP positive cells per view corresponding to 16% of hepatocytes showed GFP expression. In 
contrast, no obvious difference could be observed in rtTA or PBS injected groups (Figure 20d). 
These data indicate that both GFP and luciferase were reactivated upon HDTV injection of the 
tripartite TET1c-rtTA plasmid. Of note, neither TET1c-U nor rtTA could rescue the silenced Tet 
promoter inducible expression of luciferase.  
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Figure 20: TET1c-rtTA reactivates Tet driving GFP and luciferase expression in vivo. a.) Depiction of the 
targeting construct integrated into the R26-BiTetGFP mice. b.) Workflow of the treatments of the transgenic mice. 
2 mg/ml doxycycline was applied via the drinking water; 5 mice per group were injected with the following 
plasmids as indicated: TET1c-rtTA; PBS; rtTA; TET1-U. c.) In vivo imaging of the mice 36 hours after injection. d.) 
GFP was detected by specific antibody staining of the liver tissues from mice injected with PBS, rtTA and TET1c-
rtTA. For quantification, at least 3 samples were included for each mouse and GFP positive cells were counted in 
one field. Error bars indicate standard deviation from 3 independent samples.  
b.) 
c.) 
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HDTV mediated transfer of plasmids leads to transient expression due to the episomal state of 
transduced vectors (Liu, Gan, Yang, Zhang, & Sun, 2014; Peng et al., 2015). Thus, this 
experimental setting allows investigating whether TET1c-rtTA would enable a long-term 
reactivation of luciferase expression that is maintained even in absence of the initial trigger. Thus, 
the experiment described in the previous chapter was repeated and the expression of luciferase 
was analyzed at day 2, day 4, day 7 and day 21 after injection. TET1c-rtTA dependent activation 
of expression could be observed on day 2 and 4. Interestingly, it was found that luciferase 
expression vanished again about 7 days post injection (Figure 21b). This suggests that the 
reversion of silencing is transient, probably due to the transient expression of HDTV mediated 
expression of the TET1c-rtTA plasmid. Thus, a single administration of TET1c-rtTA is not 
sufficient to keep the Tet promoter in an active state. 
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Figure 21: Kinetics of TET1c-rtTA reactivates Tet promoter driving GFP and luciferase expression in vivo. 
a.) Workflow of the treatment of the transgenic mice. 2 mg/ml doxycycline was used applied in the drinking water; 5 
mice per group were injected with the following plasmids: TET1c-rtTA; PBS; rtTA; TET1-U. b.) Kinetics of the 
hydrodynamically injected R26-BiTetGFP mice measured in the indicated mice the IVIS over 21 days. 
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In the previous experiments the expression levels upon TET1c-rtTA expression were evaluated 
in mice pretreated with doxycycline. An obvous increase of luciferase and GFP expression was 
observed. However, these experiments do not allow the evaluation of the doxycycline dependent 
activation of transgene expression in individual mice. Thus, to evaluate the regulation capacity 
an alternative experimental setting was used. This time, all the mice were injected by HDTV in 
the non-induced state, i.e. without being treated with doxycycline. No increase in luciferase 
expression could be observed 24 hours after injection compared to day 0 as expected (Figure 22). 
Then, the injected animals were induced with doxycycline and analyzed on day2.  
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Upon doxycycline treatment all the injected animals showed an increase in luciferase expression. 
This shows that expression critically depends on the presence of doxycycline and confirms the 
regulation capacity of the TET1c-rtTA construct in the injected animals (Figure 22). 
           
Figure 22: TET1c-rtTA supports regulation of Tet-driven luciferase expression. Schematic representation of 
the experimental set up: 25 µg plasmid was injected to the tail vein as specified in Figure 21. One day after the 
injection the animals were measured in the IVIS. After the first measurements the animals were induced with 
2 mg/ml doxycycline which was applied in the drinking water. 24h after beginning of the doxycycline feeding the 
animals were measured again in the IVIS. 
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Finally, it was tested if the TET1c-rtTA mediated activation of luciferase expression could be 
repeated upon a second HDTV injection of the TET1c-rtTA. For this purpose, two cycles of 
HDTV injections were performed and the animals were analyzed according to the experimental 
schedule depicted in Figure 23a. 
After injection, a transient expression of luciferase was observed which lasted for 2-7 days. After 
21 days, the signal was completely abrogated and a second injection was applied. The luciferase 
levels were found to be highly increased, which was comparable to the first application of 
TET1c-rtTA. Thus, a reactivation of the Tet promoter in the R26-BiTetGFP mice resulted in a 
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similar expression of the construct. This confirms the conclusion that the TET1c-rtTA needs to 
be continuously present to reactivate the Tet promoter in vivo. 
 
 
Figure 23:  Repeated administration of plasmids by HDTV. a.) Schematic depiction of the experimental set up: 
the R26-BiTetGFP mice were fed with 2 mg/ml doxycycline and HDTV was performed. Luciferase was monitored 
by in vivo imaging. The injection of the indicated plasmid was repeated after 21 days while the luciferase expression 
was analysed on day 23 after the first injection. b.) Kinetics of the luciferase expression in groups of 5 mice was 
measured by bioluminescence. Error bars indicate standard deviation in these groups of mice. 
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To further confirm the general capacity of the TET1c-rtTA in reactivation of the silenced Tet 
cassettes another transgenic mouse line was investigated. This mouse carrys a Tet-controlled 
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luciferase reporter cassette in a random integration site designated as 8.10 locus (Figure 24a). 
Previous data in our lab exhibited heterogeneous luciferase expression in this mouse model 
(Riemer, Thesis). Only 38 out of 78 mice (49%) showed luciferase expression and 62% out of 
the luciferase expressing mice displayed regulated luciferase expression by doxycycline 
trearment.  
It was tested if the lack of expression in the 8.10 locus could be overcome by TET1c-rtTA. Thus, 
non-luciferase-expressing luc8.10 transgenic mice were selected for the experiment and 
subjected to HDTV injection of the TET1c-rtTA plasmid. Briefly, LUC 8.10 mice were initially 
induced with doxycycline for 7 days. Then the hydrodynamic tail vein injections of TET1c-rtTA, 
rtTA, PBS were conducted, respectively. The animals were analyzed every day in the first week 
and afterwards at day 9,11,21,29 and 42 in the IVIS. 
As shown in Figure 24c, none of the animals expressed luciferase before the application of the 
plasmids by HDTV. However, the luciferase signal of the TET1c-rtTA injected animals was 
significantly increased over a period of at least 29 days. Overall, the TET1c-rtTA injected group 
exhibited high induction (82-fold). In contrast the induction-fold of the rtTA controls groups 
were much lower (only 12-folds) (Figure 24d).  
To investigate the kinetics for the TET1c rtTA injected mice, the animals were analyzed over 
long time. The signal was found to be dropped down to the background levels after 42 days. At 
this time point, re-injection was performed to evaluate whether a reactivation of luciferase 
expression can be achieved. Similar to the reactivation pattern observed in TET1c-rtTA treated 
R26-BiTetGFP mice, the expression peak of luciferase in the LUC 8.10 mice was achieved upon 
24h-48h and disappeared 7 days post injection (data not shown here). 
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Figure24. TET1c-rtTA reactivates Tet driven luciferase expression in the 8.10 locus. a.) HDTV injection in  
LUC8.10 mice. b.) Workflow of the treatment of the transgenic mice. Doxycycline administration and HDTV 
injection was done as described in Figure 24a. Each group contained at least 3 mice (7-14 week old mice were 
chosen). The constructs used for injections are indicated as untreated group (UN) (c.) In vivo imaging of the mice 48 
hours after injection. (d.) Fold-induction of each group 48 hours post injection. Error bars indicate standard 
deviation from 3 independent samples. (e.) The time course of luciferase expression in luc8.10 mice upon HDTV 
injection with the indicated vectors. 
 
In conclusion, a reactivation of the Tet cassette by episomal expression of TET1c-rtTA could be 
confirmed in an independent chromosomal integration site.  
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4.  DISCUSSION 
The tetracycline inducible system (Tet system) has been widely used in mammalian cell lines 
and transgenic animal models by the virtue of its convenience and inducibility (Ed, 2000; 
Shockett & Schatz, 1996). However, although the system has been successfully exploited for 
many applications, there are also reports showing that the performance of the Tet system can be 
limited by epigenetic silencing resulting in severe loss of transgene expression (Pankiewicz, 
Karlen, Imhof, & Mermod, 2005; Takiguchi et al., 2013; Zhu et al., 2007a). Unfortunately, the 
experimental settings in the various studies (such as cassette design, readout, and chromosomal 
integration site) were quite different. Thus, general conclusions are hard to extract from literature 
which limits the rational improvement of the Tet system. The aim of this work was to 
systematically compare the performance of the same Tet cassette in defined genomic loci and 
develop strategies to overcome the silencing of the Tet cassette in cells and mice.  
In this study, several strategies have been utilized to achieve this aim. On the one hand, the 
performance of the Tet cassettes was evaluated at three previously identified chromosomal 
integration sites (Rosa26 locus, COL1A1 locus and the Tigre locus). Results show that in ES 
cells the Tigre locus provided the best expression of the Tet cassette. However, none of the tested 
loci supported the Tet cassette expression in mice. On the other hand, cHS4 chromosomal 
insulators were introduced into the Tet cassette to protect it from the influence of the genomic 
context. However, this exhibited only partial rescuing of the Tet cassette expression in vitro and 
in vivo. A novel strategy was developed which was based on site specific/targeted active 
demethylation of the Tet cassette by application of the methylcytosine dioxygenase subunit of 
TET1. This strategy could be shown to provide efficient activation of the silenced Tet cassettes 
both in cells and in mice in different loci, thereby overcoming the loss of expression. 
	  
4.1	  Silencing	  of	  the	  Tet	  promoter:	  impact	  of	  the	  CMV	  promoter	  element	  	  
 
An integral part of the classical Tet promoter is a minimal CMV promoter (chapter 1.1.4.2). The 
minimal CMV promoter is the streamlined version of CMV which only comprises the basic 
elements required for initiation of mammalian transcription. The native CMV (cytomegalovirus) 
promoter is routinely used for transient and stable transgene expression in various cell systems 
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and also for the production of proteins in biotechnology (Davies et al., 2011). However, it has 
been reported increasingly that this virus-derived element also can be silenced in vitro and in 
vivo (Everett et al., 2004; Morita, Arii, Christensen, Votteler, & Sundquist, 2012; Spencer, 
Gugliotta, Koenitzer, Hauser, & Wirth, 2015). For instance, Brooks and his colleagues injected 
rats with an Adenovirus containing the human fibroblast growth factor 4 (hFGF-4) gene driven 
by the cytomegalovirus (CMV) promoter and enhancer (CMV- PE). Methylation of the CMV-PE 
in the muscle at both CpG and non-CpG sites was observed 24 hours after virus administration 
and was increased at day 7 days after injection (Brooks et al., 2004). This kind of DNA 
methylation induced CMV silencing has been suggested to be a cellular defense mechanism 
against the transcription of foreign genes (Doerfler, 1992). The silencing of the CMV promoter 
in case of a single copy insertion in the Rosa26 locus has also been observed. Tchorz and his 
colleagues characterized several ubiquitous promoters (pCAG, EF1a and CMV) in the modified 
Rosa26 locus (the endogenous Rosa26 locus has been silenced) in the mice. They demonstrated 
that the ubiquitous pCAG promoter in the modified Rosa26 locus offered highest transgene 
expression, while CMV promoter did not support ubiquitous EGFP expression in the mice. The 
transgene expression could only be detected in testis, but not in salivary glands, heart, pancreas, 
liver, kidney, fat, muscle, brain and testis (Tchorz et al., 2012a). These reports are in contrast to 
the reports that are showing the CMV promoter could support long and stable transgene 
expression (F. Li, Vijayasankaran, Shen, Kiss, & Amanullah, 2014). This indicates that the 
silencing of the CMV promoter is also dependent on the nature of the chromosomal integration 
sites. Accordingly, screening for suitable sites is one frequently used method to circumvent 
silencing. 
The Tet promoter is widely used for inducible transgene expression in vitro and in vivo (Stieger, 
Belbellaa, Le Guiner, Moullier, & Rolling, 2009; Sun, Chen, & Xiao, 2007; Takahashi, 
Watanabe, Nakagawa, Kawakami, & Sato, 2008; Wang et al., 2013). However, in recent years 
the silencing of Tet promoter has also been shown. 
Wörtge and colleagues reported a mouse model carrying the Tet promoter integrated into the 
Rosa26 locus - a well described chromosomal site that has been shown to support ubiquitous 
expression of transgenes both from the endogenous Rosa26 promoter as well as upon integration 
of heterologous promoters (Zambrowicz et al., 1997). Interestingly, upon integration of the Tet 
promoter into the Rosa26 locus the mice showed very sparse doxycycline-activated expression of 
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different reporter genes in the brain, mosaic expression in peripheral tissues, and more prominent 
expression in erythroid, myeloid and lymphoid lineages, in hematopoietic stem and progenitor 
cells, and in olfactory neurons (Wörtge et al., 2010a). Furthermore, Peixin Zhu also reported in 
2007 the silencing of the Tet promoter in neurons in a mouse model generated upon random 
integration of the transgene cassette. They discovered that the Tet promoter became functionally 
silenced in the majority of neurons when the Tet promoter was inactive during development (Zhu 
et al. 2007b). Likewise, Pankiewicz and his colleagues observed the silencing of the Tet cassette 
upon random integration into the mouse genome. They found that the silenced transgene 
integrated into a poorly accessible chromatin structure (Pankiewicz et al., 2005). 
A similar phenomenon was observed in the transgenic ES and mouse lines established in our lab 
upon targeting the Rosa26 locus with Tet cassettes. Even in a clonal population of targeted ES 
cells, none of the cell lines with various cassette designs showed homogeneous transgene 
activation in individual cells (Kruse, Wirth et al., unpublished results). Moreover, only part of 
the transgenic littermates expressed the transgene while others could not give rise to any gene 
expression (Thesis Kruse, 2013). The methylation profile of the targeted Tet promoter was 
analyzed upon sorting for low and high expressing ES cells. A high CpG methylation ratio in the 
Tet promoter was discovered in low/non expressers while in contrast expressers contained 
significant lower methylation ratio (Thesis Spencer, 2014). These results indicate that the Tet 
promoter is prone to be silenced by DNA methylation which correlates to the lack of expression. 
Silencing can occur at various sites and even upon the integration into an active transcribed locus.  
In this study, the Tet cassette with the same setting was introduced to different loci by Flp 
recombinase-based RMCE. Two loci, COL1A1 and Tigre locus were used which were 
previously discussed to support regulated expression (Beard et al., 2006b; Premsrirut et al., 2011; 
Zeng et al., 2008). Interestingly, in this study, these reports could not be confirmed. Rather, the 
analysis showed that the Tet cassettes were found to be partially silenced at COL1A1 and Tigre 
locus in ES cells, and totally silenced in mice. 
The actual mechanisms associated with transgene silencing are not fully understood. Various 
factors have been shown to contribute, including the nature of integration sites, transgene copy 
number (D W Emery et al., 2000; Kong et al., 2009), methylation of the promoter regions 
(Meyer, 2013), deacetylation of histones (Oyer, Chu, Brar, & Turker, 2009) and repeated 
sequences within the transgene cassettes (Garrick et al., 1998).  
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In this thesis the RMCE targeting strategy resulted in single copy integration of cassette and thus 
could eliminate the copy number influence. On the one hand, the silencing of the Tet cassette 
upon differentiation could be overcome by DNMT inhibitors in the Tigre locus of ES cells 
(chapter 3.2), which indicated that the block of DNA methylation would protect transgenes from 
silencing. On the other hand, the active demethylation was successfully achieved by recruiting 
the dioxygenase domain of TET1 to the silenced Tet promoter in ES cells and mice (chapter 3.4). 
These results implied that the Tet promoter methylation was associated with transgenes silencing 
also in the other two loci and the silencing could be overcome. 
 
4.2	  	  	  	  Towards	  a	  predictable	  transgene	  expression	  an	  transgenic	  animals	  
 
A predictable expression of transgenes is important for a transgenic models study and antibody 
production. Basically, predictable expression is a consequence of two variables: the site of 
integration and the design of an expression cassette. 
 
4.2.1	  	  	  	  Safety	  of	  the	  characterized	  genomic	  loci	  for	  the	  targeted	  transgenesis	  
 
There are some well-characterized genomic loci, which have been reported to support 
predictable and reproducible transgene expression whilethey exhibited no detectable pathological 
disturbance to the endogenous genes. For instance, mouse models are established which rely on 
the integration of the transgene into the Rosa26 locus and are highly predictable in terms of 
transgene expression (Casola, 2010). However, also various systems with heterologous 
promoters are used - with variable success. Recently, a systematic comparison in ES cells 
showed that the Rosa26 locus does not support expression of all promoters to the same degree 
(Tchorz et al. 2012). 
As for the Tet promoter in the Rosa26 locus, unstable and heterogeneous expression of 
transgenes was observed. Haenebalcke generated an inducible mouse model which carried the 
Tet promoter driving vascular endothelial growth factor isoform 164 (VEGF164) in the Rosa26 
locus (EGFP-luciferase was included as reporters). They observed a decline of VEGF164 
expression in transgenic ES cells 11 days after culturing. Furthermore, different transgene 
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expression levels were detected in different organs in the transgenic mice established from these 
cells (Haenebalcke et al., 2013).  
Heterogeneous expression of the Tet promoter was also observed in the Rosa26 locus in this 
thesis. R26-BiTetGFP ES cells, which carry a bi-directional Tet promoter driving GFP and 
luciferase, exhibited low luciferase expression. When the cells were analyzed for GFP, only 3% 
R26-BiTetGFP ES cells showed a GFP signal, which indicated that only few cells of the isogenic 
population expressed while the others were completely silenced. This result suggests that the 
promoter was not homogenously inactivated but was inactivated in the majority of cells and thus 
overall expression is low. This might suggest the Tet promoters in different cells are undergoing 
stochastic processes, which might govern the status of the promoter. 
Of note, the silencing of the Tet promoter occurred regardless of the direction of transcription 
relative to the Rosa26 endogenous promoter (uni-direction or bi-direction) or introduced 
transgenes (luciferase or luc-HCV) (Figure 9-10). These results indicate that the silencing of the 
Tet promoters does not depend on different transgenes or cassettes design. 
However, silencing of the Tet promoter seems to be highly dynamic. Wan and his colleagues 
established CMV-GFP mice that ubiquitously express the rtTA from the Rosa26 locus and also 
carry a Tet-GFP cassette inserted into the COL1A1 locus as a single-copy gene. They found that 
fetal doxycycline exposure/rtTA activation led to silencing of the COL1A1 integrated Tet-GFP 
cassette in adult mice. They further gave evidence that the inheritance of epigenetic perturbation 
was dependent on the timing of the perturbation as well as the location of the perturbation (Wan 
et al., 2013). 
In this thesis, the silencing of the Tet cassette was also observed in the loci other than the Rosa26 
locus: COL1A1 locus and Tigre locus in transgenic mice. As shown in 3.1.1, although the Tet-
luciferase/GFP expression could be detected in ES cell state to a certain extent upon in vitro/ in 
vivo differentiation no Tet-luciferase/GFP expression could be detected at all. This implies that 
differentiation during embryonic development might also contribute to the silencing of Tet 
promoter. 
These facts indicate that even the well characterized genomic loci could hardly guarantee 
transgene expression in vitro and in vivo. The expression fashions of transgenes depends on 
targeting constructs, targeted transgenes (Figure 9-10), the types of the cells (Zhu et al., 2007a) 
and even the stages of the embryonic development (Wörtge et al., 2010a). 
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4.2.2	  	  	  Improve	  the	  targeting	  vector	  by	  introducing	  chromatin	  modifiers	  	  
 
The silencing of the Tet promoter was proposed to be overcome by introducing proper 
chromosomal elements that could shield the constructs from negative influences of the 
integration site. These chromosomal modifiers could protect the constructs either by keeping the 
chromatin open and/or by protecting the transgene cassettes against negative effects like 
heterochromatin spreading (Nair, Jinger, & Hermiston, 2011; Quilici et al., 2013; N. Uchida, 
Hanawa, Yamamoto, & Shimada, 2013; F. Zhang et al., 2010b).  
A chromatin insulator is one of the described chromosomal modifiers. It is a DNA sequence 
which has been shown to protect a target gene from the position effects exerted by neighboring 
domains (Burgess-Beusse et al., 2002; Recillas-Targa et al., 2002). The cHS4 insulator, which 
was used in this thesis, is a 1.2 kb DNA element originally derived from the 5’ regulatory region 
of the chicken β-globin locus (Chung, J H). Previous reports have shown that by insertion of one 
or two copies of the 5’HS4 full length elements or only the core elements, one could protect the 
transgene from silencing (Bell, West, and Felsenfeld 1999). cHS4 insulators have also been used 
to optimize the Tet cassette. Shi reported in 2011 that the cHS4 element could improve Tet 
cassettes upon random integration as achieved by lentiviral gene transfer. This resulted in a 
better transgene expression compared to the expression without using insulator (Shi et al., 2014).  
However, high variability in the expression of cHS4 modified Tet cassettes was observed in this 
thesis. Although elevated luciferase expression was observed in some cHS4 modified Tet 
cassette targeted ES clones, also clones were identified which showed no improvement at all 
(Figure 14). This was unexpected since the clones were generated upon RMCE and can be 
considered to be genetically identical (isogenic). These data indicate that cHS4 chromatin 
insulator could not robustly shield the Tet cassette in the Rosa 26 locus in targeted ES clones. 
These results are in accordance with the report published by Grajevskaja in 2013. They observed 
that the cHS4 insulator failed to shield the thenkx2.5 promoter from position effects in zebrafish 
(Grajevskaja, Balciuniene, & Balciunas, 2013). In their study, they introduced 1.2 kb cHS4 
insulators to a RFP expression cassette driven by lens-specific gamma-crystalline promoter in the 
zebrafish genome. They found that flanking a transgenic construct by cHS4 insulation sequences 
lead to overall increase in the expression of RFP. However, a very high degree of variability of 
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RFP expression with respect to embryos was also observed, which indicated cHS4 insulators fail 
to fully protect transgene expression in this setting. 
The failure of cHS4 insulator in fully protecting the Tet cassette is not clear. The reasons could 
be that the construct setting in this thesis was different from the literature which fulfilled robust 
protection of transgenes by cHS4 insulators, or the dysfunction of cHS4 in the specific locus or 
in combination with the Tet promoter.  
 
4.3	  	  	  	  Rescue	  of	  the	  transgene	  expression	  by	  targeted	  demethylation	  	  
 
Naturally, DNA demethylation happens during the mammalian development and other biological 
processes like sperm/ eggs reprogramming after fertilization (Gu et al., 2011). It is the direct 
removal of a methyl group independently of the DNA replication. The mechanism of the natural 
active DNA demethylation has been unclear for a long time. However, in 2009, Zhang and his 
colleagues showed that Ten-eleven translocation methylcytosine dioxygenase 1 (TET1) protein 
possesses enzymatic activity capable of hydroxylating 5-methylcytosine (5mC) to generate 5-
hydroxymethylcytosine (5hmC) by oxidation of 5mC in an iron and α-ketoglutarate dependent 
manner. This conversion of 5mC to 5hmC has been proposed as the initial step of active DNA 
demethylation in mammals (Wu & Zhang, 2011). The TET1 protein is composed of a methylated 
CpG (MeCpG) binding domain and a catylatic domain (H. Zhang et al., 2010). The separated 
MeCpG binding domain and the catalytic domain of TET proteins provide the possibility of 
redirecting the protein to specific loci of choice. 
DNA demethylation could also be achieved un-naturally. For years researchers utilized Aza to 
inhibit DNMTs during the synthesis of new DNA strands. In this case the methylation of the new 
DNA strands would not occur. Therefore, the blocking of DNMTs is an induced, replication-
dependent and non-natural process. However, their toxicity resulted from the global impact on 
the whole genome and replication-dependent demethylation (because DNMT inhibitors could 
only inhibit methyl group transfer on newly synthesized DNA) pattern still largely limited their 
practical applications (Jüttermann, Li, & Jaenisch, 1994).  
 
4.3.1	  	  	  	  Response	  variability	  to	  TET1c-­‐rtTA	  within	  treated	  mice	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In this study, TET1 was successfully utilized for targeted demethylation by fusing the catalytic 
domain of TET1 with the transactivator rtTA, which specifically binds the Tet promoter (TET1c-
rtTA). Reactivation of the Tet cassettes in different loci in ES cells and mice was achieved by the 
overexpression of a plasmid encoding TET1c-rtTA. In the ES cells carrying a silenced Tet 
cassette in the Tigre locus or in Rosa26, transient transfection of TET1c-rtTA led to an increase 
of the transgene expression (Figure18-19). This demonstrates the reactivation in different 
integration loci and different construct settings. In silenced mice, 50-120 -fold improvement of 
transgene expression could be detected 36-48 hours after delivery of the plasmid via HDTV 
injection, which indicates that the reactivation of the Tet cassettes could even be achieved in the 
mice (Figure20-21). 
However, among all TET1c-rtTA injected R26-biTetGFP mice, 2 failed to show an elevated 
luciferase signal. This did not correlate with the level of background expression level since the 
expression differences among the mice prior to injection were not significant (data not shown). 
Interestingly, these none-responders could neither be reactivated by Aza treatment. A similar 
impairment to reactivate the expression was also observed in the tested silenced ES clones. For 
instance, the luciferase signal of the Tigre-TetHCVsWT ES clone 3-1 and the Tigre-Tetlucs ES 
clone 1-3 increased pronouncedly after both TET1c-rtTA and Aza treatment. Nevertheless, the 
stable silencers like Tigre-TetHCVsWT ES clone 2-5 and Tigre-Tetlucs ES clone 4-1 responded 
neither to the treatments (Figure 19). These data suggest that there might be different states of 
epigenetic silencing and only some of these states can be reversed by demethylation. 
Furthermore, the silencing states might be different even within a clonal population of cells 
(Figure 18-19). 
Epigenetic repression of gene expression might be divided into different phases characterized by 
different combinations of DNA/histone modifications, such as DNA methylation, histone 
acetylation / methylation / phosphorylation / ubiquitination / sumoylation (Chahwan, Wontakal, 
& Roa, 2010; Dhar, Vishal, Sharma, & Kaul, 2014; Gaál & Oláh, 2014; Matzke & Mette, 2000; 
Ptashne, 2007). These phases might accumulate or self-reinforce over time (Lachner et al., 2001). 
As proposed in Figure 25, when the chromatin is in a fully active state and all the activation 
markers bind, transcription is ongoing. However, once the ultimate silencing state is achieved 
(all the silencing collaborators are recruited on the promoter), the chromatin is so condensed that 
a solid and stable repression of the promoter is achieved. Such a state will be sustained and hard 
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to change. However, also intermediate states could exist in which the chromatin state stays in 
between of these two extreme states. In such an intermediate state, the chromatin is plastic that 
could easily be converted by epigenetic modifiers like Aza or - like in this study – by enzymatic 
demethylation of the promoter.  
 
 
 
Figure 25. The transition from the active chromatin to the silent chromatin. The chromatin is considered to 
have three states: active, intermediate and silenced. In the intermediate phase chromatin is plastic and dynamic and 
can easily be converted by epigenetic modifiers (e.g. demethylateon). When all the silencing collaborators team up 
on the promoter, the ultimate silencing phase is achieved and the repression of the promoter can not be reverted. 
HAT - Histone acetyltransferase; DNMTs -	   DNA methyltransferase; HDACs - Histone deacetylase; Cm - 
methylated cytosine. 
 
During the silencing process, the relationship between the two major epigenetic modifications -
DNA methylation and repressive histone modifications, i.e. the dynamics of the modification, is 
still unclear until now (François Fuks, 2005). On the one hand, some scientists proved that DNA 
methylation is followed by repressive histone modifications. One example is represented by 
Lehnertz and coworkers who observed that loss of H3K9 methylation in histone-lysine N-
methyltransferase SUV39H1 ES cells could decrease Dnmt3b-dependent CpG methylation at 
major centromeric satellites in mammals (Lehnertz et al., 2003).  
On the other hand, there is also evidence that DNA methylation is a prerequisite for repressive 
histone modifications. For example, Fuks and coworkers found that the methylated CpG 
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dinucleotides recruited MeCP2 (methyl CpG binding protein 2), which furthermore recruited 
histone deacetylase (HDAC) to the methylated DNA. This results in chromatin remodeling and 
reinforce the silencing status in vivo (Francois Fuks et al., 2003). Thus, they suggested a model 
for a self-reinforcing epigenetic cycle that might strengthen a repressed chromatin state (Figure 
26). 
 
 
 
Figure 26. Model for a self-reinforcing epigenetic silencing state to strengthen a repressed chromatin state. 
CpG is firstly methylated with the help of DNMT and the methylated CpG allows the binding of methyl-CpG-
binding domain (MBD) proteins like methyl CpG binding protein 2 (MeCP2) to DNA. Afterwards, histone 
deacetylase (HDAC) will be recruited to H3K9 and induces H3K9 deacetylation. H3K9 deacetylation would result 
in histone methylation as deacetylation of H3K9 is necessary for methylation. Furthermore, some specific adaptors 
will then bind to this repressing complex and recruit again DNMTs to reinforce these silencing procedures.  
 
Combining the model in Figure 25 and model in Figure 26, the data in this thesis implie that not 
only DNA methylation contribute to the heterogeneous expression pattern of the Tet cassettes in 
the cells and the mice, but also other histone modifications might play roles in this process. For 
the cells and mice that did not respond to the treatment, the silencing might have been reinforced 
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by all the silencing factors all the time and finally achieved the ultimate silencing state; and the 
responding cells were in plastic state. 
 
4.3.	  2	  	  	  	  	  Rescue	  of	  the	  Tet	  cassette	  by	  TET1c-­‐rtTA	  is	  reversible	  
 
Interestingly, the rescuing of the Tet cassettes by TET1c-rtTA was transient both in vitro and in 
vivo (Figure 18-19 and 20-24). For R26-biTetGFP mice the reactivation of luciferase could be 
detected only for a period of 7 days, while the TET1c-rtTA treated LUC8.10 mice showed a 
reactivation of luciferase for 21 days. In both cases luciferase expression level dropped to the 
background levels afterwards. This was also observed in silenced R26-biTetGFP ES cells 
tranfected with TET1c-rtTA: after one week the reactivation of GFP vanished (data not shown). 
Of note, re-administration of TET1c-rtTA could re-activate the signal. However, this was also 
found to be temporal. 
This reversibility of reactivation might be the result of the method for applying the plasmid 
which was achieved by HDTV injection (for mice) and transfection (for cells). The HDTV 
injection is a highly efficient procedure to deliver nucleic acids to the liver in small animals. By 
HDTV injection, the plasmid DNA is mainly taken up by the liver and 5-25% hepatocytes could 
take up the plasmids (Budker et al., 2006). The expression peak of the delivered DNA is usually 
observed within 12-24 hours, and diminishes after 20-40 hours. This transient expression is 
attributed to the degradation of the plasmids. Furthermore, less than 1% plasmids has been 
reported to integrate in the host genome by chance (Crespo et al. 2005; Kovacsics and Raper 
2014; Liu et al. 2014; Peng et al. 2015; Suda et al. 2007).  
Therefore, the transient reactivation upon injection of TET1c-rtTA by HDTV suggests that the 
Tet promoter was silenced again as soon as the expression of the TET1c-rtTA declined and the 
silenced epigenetic state was restored. Thus, a constant expression of TET1c-rtTA would be 
needed for keeping the Tet promoter in an active state.  
Furthermore, this observation might also imply that some repressive mechanisms are ongoing 
that set in as soon as the demethylated state is not actively maintained.  
 
4.3.	  3	  	  	  	  Targeted	  genomic	  suppression/activation	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DNA methylation-induced transgene silencing do not only hampered the antibody production in 
industry (Spencer et al., 2015) but is also a big problem for transgenesis research (Nair et al., 
2011).  
In this thesis the catalytic domain of TET1 was fused with the rtTA to engineer a fusion protein 
TET1c-rtTA for targeted demethylation of the Tet promoter. As shown in Figure 20-24, the 
engineered TET1c-rtTA fusion has reactivated the Tet cassette in silenced mice and ES cells 
irrespective of the integration locus. 
Targeted demethylation has been shown in 2013 for an endogenous promoter. By combining 
TET1 hydroxylase catalytic domain with site specific DNA binding motifs targeted 
demethylation of human endogenous RHOXF2 gene and HBB gene in Hela and HEK293 cells 
could be achieved (Maeder et al., 2013a). They fused engineered transcription activator–like 
effector nuclease (TALEN) repeat arrays (targeting either RHOXF2 gene or HBB gene) with the 
TET1 hydroxylase catalytic domain. Using these TALE-TET1 fusions, they could recruit the 
demethylation domain to the respective promoter. Thereby they demonstrated that a 
demethylation of critical promoter CpG positions could be achieved and led to substantial 
increase in the expression of the targeted endogenous human genes. However, the increase was 
still transient due to the loss of the plasmids (Maeder et al. 2013a). Soon after that, another study 
proved that when TET2 was fused to locus guiding Zinc fingers specific for ICAM-1, it 
successfully reactivated ICAM-1 gene in human ovarian cancer cell line A2780 (Chen et al., 
2014).  
However, the targeted demethylation in both research studies was very restricted to 1-3 specific 
CpGs, which might limit the reactivation efficiency. Furthermore, all performed targeted 
demethylation studies were achieved in cells and not in mice up to now. In this thesis the 
catalytic domain of TET1 could be recruited to not only one specific position but (due to the 7 
repeats) moreover to several sites. This applied method was proved to work not only in cells but 
also in mice. This suggests that this approach might be more powerful than the published ones 
and is not limited to in vitro studies. 
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5.  OUTLOOK 
The results of this study provide proof of principle that efficient reactivation of silenced Tet 
cassettes can be achieved by targeting the demethylating domain of TET1 to the Tet promoter 
sequence. This is the first time targeted demethylation of the Tet promoter has been actualized by 
utilizing TET1. It is predictable that this approach will be a powerful tool to rescue other 
silenced Tet transgenic mice. This could be achieved by viral transfer of the TET1c-rtTA to the 
respective cells. As the study pointed out, a constant expression of the TET1c-rtTA is required. 
To maintain a constant TET1c-rtTA expression in mice, a TET1c-rtTA transgenic mouse strain 
could be established and crossed to the silenced Tet mice. Thereby, a stable and targeted 
demethylation would be expected.  
The results of this study highlight the complex epigenetic modulation of the Tet cassettes in 
various sites of the mouse genome. While the study shows that certain strategies for 
demethylation can improve the expression, a robust activation of particular genomic sites might 
require a chromosomal context that prevents spreading of negative influences to the transgene 
cassettes. In this study, it was shown that cHS4 could not fulfill this task. However, other 
chromatin modifiers, which have been reported to stabilize transgene expression, could be 
evaluated alone or in combination with the current demethylation strategies. For instance, matrix 
attachment regions (MARs) or a ubiquitous chromatin opening element (UCOE) (Majocchi et al., 
2014; F. Zhang et al., 2010a) could be introduced into the constructs.  
In this study, the induced epigenetic modulation was restricted to DNA demethylation. As 
discussed, other mechanisms might also contribute to silencing and self-reinforcing in particular 
an active histone repressing machinery. Therefore, to better reactivate the Tet promoter histone 
modifying enzymatic activities (e.g. histone acetylase or histone methylases) would need to be 
recruited. For this purpose, the rtTA could be exploited for generating fusion proteins that bind 
specifically to the Tet promoter. Thus, targeted DNA demethylation and histone modulation 
could be achieved by the combined administration of both the TET1c-rtTA and histone 
modulating fusion proteins. It could be envisaged that thereby the stability of the demethylated, 
active status of the promoter might be increased. 
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Moreover, this strategy is not restricted to the Tet promoter but could also be utilized for 
endogenous promoters or any other DNA sequences or histone modification. For instance, with 
the help of guide RNA from CRISPR/Cas9 system (Hsu et al., 2014) or TALENs (Juillerat et al., 
2014), the catalytic domains for DNA demethylation/histone modification could be recruited to 
the sequences that might ‘poison’ the locus and induce silencing.  
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7.  APPENDIX 
7.1	  	  	  Tagged	  ES	  cells	  and	  targeting	  strategy	  	  
 
 
 
a.) 
b.) 
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Figure S1: FLP dependent targeting strategies for different loci: a.) The Rosa26 locus lies on chromosome 6 in 
between the setd5 gene and Thumpd3 gene. It has been tagged by heterospecific FRT sites (FRT wt and FRT 
Mutant) after the first exon (RosaAntiluc/G4B12 ES cells) (Sandhu et al., 2011). The targeting cassette carries the 
same heterospecific FRT sites. The Tetracycline inducible cassettes are flanked by such heterogeneous FRT sites 
(targetable plasmid) allowing the recombinase (FLP) mediated cassette exchange (RMCE) into the tagged locus. b.) 
The COL1A1 locus lies on chromosome 17 in between the HILS1 gene and SUMO02P7 gene and has been tagged 
after the fifth exons (Beard et al.,). The tagged COL1A1 locus carries two FRT wt sites. In between a PGK promoter 
driving neo resistance and poly A signal is placed. Thus, upon targeting the full plasmid will be integrated into the 
locus including the bacteria backbone, while the PGKneopA will be deleted c.) The Tigre locus is located on 
chromosome 9 in between of the AB124611 gene and Carm1 gene. A Bacterial Artificial Chromose (BAC) vector 
comprising this locus was modified with FRT and FRTmut sites in vitro and randomly transferred to ES cells. A 
clone carrying a single copy of this BAC was isolated (Wirth, et al., not published). For targeting, a cassette flanked 
by the same FRT and FRTmut sites is introduced in Tigre locus upon FLP treatment. 
 
 
 
c.) 
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7.2	  	  	  Abbreviation	  	  
 
5’HS4 constitutive DNase I-hypersensitive site 
5caC 5-carboxylcytosine 
5fC 5-formylcytosine 
5hmC 5-hydroxymethylcytosin 
5mC 5-methylcytosine 
alcA alcohol dehydrogenase I 
AML acute myeloid leukemia 
ANK1 Ankyrin 1 
AZA 5-azacytidine 
BER base excision repair 
CCL4 Carbon Tetrachloride 
CGBP CpG-binding protein  
ChIP                                             Chromatin Immunoprecipitation  
cHS4   Chicken β-globin insulator 
CL    clone 
CMV cytomegalovirus promoter                  
COL1A1 type I collagen locus 
CRISPR-Cas    Targeted transgenesis based on cas9  
DNA nuclease enzyme mediated DNA double-strand breaks 
CTCF CCCTC-binding factors 
CXXC domain CXXC-type zinc finger protein binding domain 
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DEC      Decitabine 
DME Demeter 
DNMT DNA methyl-transferases 
dNTP  deoxyribonucleotide triphosphate  
DOX    Doxcycline 
DSBs double-strand breaks 
E.coli   Escherichia coli 
EB embryoid bodies 
ER estrogen receptor 
ES embryonic stem cells 
FACS Fluorescence-activated cell sorting 
FCS  fetal calf serum  
Fibro-L      fibroblast like cells 
FR folate receptor  
FRT flippase recognition target sites 
GFP  green fluorescent protein  
GOI gene of interest 
GR glucocorticoid receptor 
GSH Genomic safe harbor 
H11 Hipp11 
HAT histone acetyltransferase 
HCV Hepatitis C Virus 
HDAC Histone deacetylase 
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HDTV Hydro dynamic tail veil injection 
Hep-L Hepatic-like  
HR homologous recombination 
ICR imprinting control region 
JFH1 subgenomic replicon of HCV 
kb  1000 base(s)  
KO  knock out  
LHFPL4 Lipoma HMGIC Fusion Partner-Like 4 Protein 
MBPs methyl binding proteins 
MeCP2 methyl CpG binding protein 2 
MEF mouse embryonic fibroblast 
MHC major histocompatibility complex 
MLL mixed-lineage leukemia 
mRNA messenger RNA  
MTMR14 Myotubularin-related protein 14 
NHEJ non-homologous end-joining 
PBS  phosphate buffer saline  
PCR polymerase chain reaction  
PEV position effect variegation 
PI pronuclear injection   
PTetbi Bi-directional Doxycycline (Tetracycline) inducible promoter 
RIGS repeat-induced gene silencing 
RMCE recombinase mediate cassette exchange 
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ROS1 repressor of silencing 1 
Rosa26 gene trap ROSA 26 locus 
rtTA      reverse tetracycline transactivator 
SAM S-adenosyl-L-methionine 
SETD5 SET Domain-Containing Protein 5 
sgRNA guide RNA 
SRGAP3 SLIT-ROBO Rho GTPase activating protein 3 
TAF transcription initiation factor 
TALENs transcription activator-like effector nucleases 
TBP TATA-binding protein 
Tet Tetracycline (doxycycline) inducible expression cassette 
Tet promoter Doxycycline (Tetracycline) inducible promoter 
TET1 Ten-eleven translocation methylcytosine dioxygenase 1  
TET1c  Catalytic domain from TET1 protein 
TET1c-rtTA Catalytic domain from TET1 protein fused with rtTA 
TET1c-unspecific Catalytic domain from TET1 without binding domain 
Tet-O bacterial Tet-operator 
Tet-Off tTA dependent inducible expression system 
Tet-On  rtTA dependent inducible expression system 
TetR Tetracycline repressor protein 
THUMPD3 THUMP Domain-Containing Protein 3 
TIigre tightly regulated locus 
tracr RNA trans-activating CRISPR RNA 
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Tris  tris hydroxymethylaminomethane  
tTA       TetR+VP16 
 UCRs ultra-conserved regions 
USFs upstream stimulatory factors 
UV ultraviolet 
VC    Ascorbic acid 
Vezf1 vascular endothelial zinc finger 1 
VPA  valproic acid 
ZF zinc finger nucleases 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 
117 
 
7.3	  	  	  list	  of	  figures	  
 
Figure 1: Principle of RMCE. 
Figure 2: Principles of Tet-on inducible system. 
Figure 3: Mechanism of DNA methylation at cytosines. 
Figure 4: Mechanism of DNA methylation induced gene suppression. 
Figure 5: The conserved structures of TET protein family. 
Figure 6: The step-wise cytosine demethylation mechanism. 
Figure 7. Schemes elucidate mechanism of enhancer blocking insulator and barrier insulator. 
Figure 8: The chicken HS4 insulator. 
Figure 9: Evaluation of 3 chromosomal loci for the expression of Tet cassette. 
Figure10:  Heterogeneous GFP expression from the Tet promoter in mouse ES cells. 
Figure 11: Tet controlled Luciferase expression in the Tigre locus upon in vitro differentiation 
Figure12: Expression level of Tet cassette in the Tigre locus upon in vitro differentiation to 
hepatic like cells in presence of 5-azacytidine. 
Figure13: Tet-dependent luciferase expression level of ES clones within the Rosa locus with or 
without cHS4 insulator. 
Figure14: Expression pattern of the insulated Tet cassette in the Rosa26 locus upon in vitro 
differentiation. 
Figure15: Expression level of the insulated Tet cassette in the Rosa26 locus in teratoma derived 
cells. 
Figure 16: Schematic representation of the expression constructs for targeted demethylation. 
Figure 17: Transactivation potential of TET1c-rtTA in 293T cells. 
Figure 18: TET1c-rtTA induced GFP reactivation in ES cells in Rosa26 locus.   
Figure 19: TET1c-rtTA induced reactivation of luciferase in ES cells in the Tigre locus. 
Figure 20: TET1c-rtTA reactivates Tet driving GFP and luciferase expression in vivo. 
Figure 21: Kenitics of TET1c-rtTA reactivates Tet driving GFP and luciferase expression in vivo. 
Figure 22: TET1c-rtTA supports regulation of Tet driven luciferase expression. 
Figure 23: Repeated administration of plasmids by HDTV 
Figure24: TET1c-rtTA reactivates Tet driven luciferase expression in the 8.10 locus. 
Figure 25: The transition from the active chromatin to the silent chromatin. 
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Figure26: Model for a self-reinforcing epigenetic silencing state to strengthen a repressed 
chromatin state. 
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